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As a crucial step in the quest of understanding the functioning of the cell on the molec-
ular system level, the genomes of many species, including human, have already been
largely decoded. The knowledge of the list of human genes that has been obtained
by these efforts is essential but insufficient for elucidating cellular processes in health
and disease. It is clear that the separate genes execute their functions through inter-
actions between each other as well as with different other biomolecules. Knowledge of
the complex functional interplay between all biomolecules in the cell promises to take
us a step further toward understanding the molecular mechanisms governing life. This
chapter gives a coarse summary of several types of biomolecular interactions and the
most prevalent ways they are detected, stored, modeled, and utilized for the interpre-
tation of gene expression data. A particular focus is put on current problems in the
field that motivated this thesis.
1.1 Molecular interactions
The interplay between two or more biomolecules that has a specific biological effect is
called an interaction. Interactions, rather than the separate physical entities (genes,
proteins, metabolites, etc.), are the key drivers of biological processes. Deviations from
the normal interaction patterns in the cell can lead to disease, thus it is not surpris-
ing that they constrain genome evolution (56). Interactions are commonly divided into
several classes depending on the type of the interacting molecules, the mechanism, speci-
ficity, duration, and our understanding of their biological effects. Examples for such
1
1. INTRODUCTION
interaction classes are gene regulatory interactions, metabolic reactions, signaling reac-
tions, and protein-protein interactions: 1) Gene regulatory interactions are executed by
the products of certain genes called transcription factors that bind specifically to the
DNA at certain regions within or near other genes to enhance or repress their expres-
sion. 2) Metabolic reactions are biochemical reactions that convert metabolites from
one type to another under the catalysis of specific enzymes (mainly proteins or protein
complexes). 3) Signaling reactions are another type of biochemical reactions, typically
involving proteins being modified (e.g. phosphorylated or cleaved) by other physical
entities in order to initiate or transmit a biological signal. 4) Protein-protein inter-
actions are a general class of physical interactions between proteins. They may have
different stability (depending on the biochemical properties of the interactors), e.g. the
formation of protein complexes usually results from protein-protein interactions that
are stable over time, while modification reactions, for example, are administered by
more transient interactions between the modifier and the protein being modified.
A biological pathway can be seen as a compilation of interactions sharing partici-
pants and constrained in space and time, which together concert a biologically relevant
transformation of mass or a conduction of a biological signal. It is a key point that
biological processes are usually composed of many different types of interactions. As an
example, the diagram in Figure 1.1 depicts the Insulin signaling pathway that simul-
taneously involves protein-protein interactions (e.g. between insulin and its receptor
on the cell surface), biochemical reactions (e.g. hydrolysis of GTP by RAS, modu-
lated by GAP), and gene regulatory interactions (e.g. regulation of target genes by the
C-JUN:C-FOS complex).
1.2 Interaction data
1.2.1 Detection and prediction of interactions
Obtaining knowledge of all interactions in the cell promises mechanistic insight into
cellular biology in health and disease as it reveals the molecular circuitry behind bi-
ological processes. This motivates contemporary biologists around the globe to apply
immense efforts in designing and applying various techniques to discover the different
interactions in the cell of human and of other species. Direct gene regulatory inter-
actions, for instance, are commonly predicted by ChIP-chip (21) or ChIP-seq (120) –
2
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Figure 1.1: Insulin signaling pathway. Like all other biological processes, the in-
sulin signaling pathway comprises different types of interactions including protein-protein
interactions, biochemical reactions and gene regulation. Reproduced from BioCarta
(http://www.biocarta.com) and modified.
experimental techniques which involve chromatin immunoprecipitation (ChIP) coupled
to DNA binding site identification through hybridization or sequencing, respectively.
On the other hand, metabolic and signaling reactions are typically detected through
narrow-focused biochemical experiments such as enzyme assays (64), or are deduced
from specific crystallographical measurements (22). Finally, protein-protein interac-
tions are detected mostly with yeast-two-hybrid (Y2H) screening (52), affinity purifica-
tion coupled to mass spectrometry (AP-MS) (1), or protein-fragment complementation
assay (PCA) (59). The advantages and disadvantages of these and of other protein
interaction detection techniques are discussed in (137). In addition to experimental
techniques for the direct detection of interactions, different computational methods
have been developed for the prediction of such. For example, many methods exist
that can predict potential protein-protein interactions based on genomic sequence or
homology data (88, 145, 147).
Interaction data resulting from the application of experimental or computational
methods may have binary or complex nature. Binary interactions have exactly two
3
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participants, while complex interactions may involve an arbitrary number of physical
entities. For instance, protein-protein interactions detected by Y2H and PCA strictly
involve two participants (which may be identical in the case of self-interactions) because
these methods test pairs of proteins for direct associations. On the other hand, interac-
tions detected with AP-MS are generally complex while the direct physical interactions
between the separate proteins are not revealed by this technique. Biochemical reac-
tion data have a complex nature as well since such interactions may involve multiple
substrates that are converted to multiple products.
1.2.2 Storing and representing interaction data
Interactions that have been detected or predicted are usually assembled in specialized
interaction knowledge bases through literature mining or direct data submissions (41).
Most of these knowledge bases offer public access to their content through querying and
visualization of interactions. Currently, interaction data are scattered among more than
three hundred such databases (11). Due to their specific focus, each of the databases
contains a limited number of interaction types (mostly one to two types). Moreover,
even databases with similar focus on interaction type have limited overlap with each
other. This is mainly because the creators of each database tend to capture interac-
tions from a unique subset of sources (e.g. literature publications) according to their
own curation rules. Thus, in a sense, our knowledge of a specific biological process
is dispersed among many interaction resources, which constrains a system-level view
on that process (35). The same is true from the perspective of a specific gene: The
detected protein-protein interactions of its products are scattered across protein inter-
action databases; data on its enzymatic functions resides in metabolic databases; and
its gene regulatory interactions are assembled in databases on gene regulation. The
complete picture of the gene’s different roles in the cell can be obtained only after in-
tegrating all of these interaction resources. Such a comprehensive picture is crucial for
example in drug development to predict the possible impact from drug target binding
on the human body (35). Unfortunately, the task of interaction data integration is
hindered particularly by the vast heterogeneity of current databases in respect to data
models and data exchange formats: each database has its own way of representing,
storing, and providing access to the interaction data. The problem has been partially
solved by defining standard file formats for representing molecular interactions. The
4
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most widely used formats include BioPAX, PSI-MI and SBML (154). They differ in
the representable types of interactions and the level of detail they can provide for the
individual interactions. For example, PSI-MI is specialized to represent physical inter-
actions, while SBML is designed to describe biochemical reactions and their kinetics.
Probably the most descriptive of these three is BioPAX, which is able to represent a
wide range of interaction types between a variety of physical entity types. Nevertheless,
despite the efforts spent in the development of standard interaction representation for-
mats, the data models of many interaction databases are often incompatible with these
formats. Therefore, many databases have either adopted none of the standard formats,
or the standardized data are often incomplete or inaccurate with respect to the original
database content. This is why database-specific data formats are still primarily used
by interaction resources as the means to distribute their content. The bottom line is
that to integrate data from the existing highly complementary databases in order to
obtain a more complete picture of cellular processes, one still has to deal mainly with
database-specific data formats that are incompatible with each other, or with several
standard formats representing the database content in a possibly imprecise manner.
1.2.3 Noise in interaction data
Interaction data are not only incomplete from the perspective of each individual database,
but they may also be noisy. Above all, existing large-scale protein-protein interaction
data have been shown to contain a considerable portion of false positives (72, 114),
i.e. reported interactions that do not take place in reality. All techniques for detecting
protein interactions generate false positives, for example due to experimental errors or
bias (technical false positives). Adding to this, some of the interactions measured in
vitro do not actually take place in vivo, for example because the proteins are separated
in different cellular compartments (biological false positives) (105). Interactions col-
lected from the literature are additionally prone to curation errors that may also reach
striking magnitudes (41).
The integration of interaction datasets by considering their union increases the cov-
erage of the real interactome (thus decreasing the false negative rate, i.e. the proportion
of missing true interactions), albeit this is often achieved at the expense of a higher
false positive rate (that is, the proportion of spurious interactions) in the integrated
data compared to the separate datasets. The reason is that true interactions, being a
5
1. INTRODUCTION
very small subset of all possible tuples of physical entities, have a much higher prob-
ability to be found simultaneously in two independent interaction datasets than false
interactions. Thus, the number of true interactions saturates much faster in the process
of data integration compared to the number of false positives. As a consequence, false
positive interactions are accumulated at high rates in integrated datasets.
1.2.4 Graphical modeling of interaction data
Interaction data are usually modeled as network graphs or hypergraphs (2, 100). Such
modeling benefits from the existing palette of graph-theoretical methods aiding the
analysis of interaction data.
An interaction graph is a pair G = (V,E) where V is a set of nodes, conventionally
representing physical entities like genes, proteins, complexes, metabolites, etc., and
E is a set of edges (or pairs of nodes), each edge usually representing an interaction
between two nodes. A graph is connected if any pair of its nodes are linked with
each other through a finite path of edges in the graph. Otherwise, the graph consists
of multiple connected components. A graph is directed if its edges have a specified
orientation, i.e. one of the nodes is designated the edge source and the other node
is the edge sink. If edges have no orientation, the graph is called undirected. Binary
protein-protein interaction data (i.e. interactions involving pairs of proteins) are usually
modeled as undirected network graphs because of the symmetrical nature of protein-
protein interactions (Figure 1.2). On the other hand, gene regulatory interaction graphs
are directed because for every interaction, one of the genes is the regulator and the other
is the regulated gene, but generally not the other way around (Figure 1.2). Special
classes of graphs are multigraphs and bipartite graphs. In multigraphs, more than one
edge can connect the same pair of nodes, for example to indicate different types of
relations between these nodes. A bipartite graph G = (V1, V2, E) has two disjoint sets
of nodes denoted V1 and V2, with edges of E connecting nodes from V1 with nodes
from V2 while no edges connect nodes within V1 or within V2. Unlike simple graphs
with uniform nodes, which are able to represent only binary relations, bipartite graphs
can be used to model complex interactions (i.e. interactions with an arbitrary number
of participants). For instance, biochemical reactions are often modeled as directed
bipartite graphs where V1 is the set of physical entities, V2 is the set of reactions, and
directed edges connect reactions with their participants that can be any number (Figure
6
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Figure 1.2: Modeling interaction data as graphs or hypergraphs. Binary interac-
tions like physical interactions between pairs of proteins and gene regulatory interactions
are modeled as undirected and directed graphs, respectively. Complex protein interactions
are often decomposed into binary interactions following the spoke or matrix models, or are
modeled as undirected bipartite graphs or undirected hypergraphs. Biochemical reactions
are modeled as directed bipartite graphs or directed hypergraphs.
1.2). Here, edge orientation conventionally indicates whether an entity is a reaction
substrate or product.
An alternative to bipartite graphs for modeling complex interactions are hyper-
7
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graphs (100). A hypergraph H = (V,E) consists of a set of nodes V and a set of
hyperedges E. Unlike edges in graphs, which connect exactly two nodes (or one node
with itself in case of self-interactions), hyperedges may connect an arbitrary number of
nodes. Hypergraphs may be directed, in which case a subset of the nodes in each hyper-
edge are designated source nodes and the rest are sink nodes. Directed hypergraphs are
sometimes used for representing metabolic reaction systems (Figure 1.2). Undirected
hypergraphs rather than network graphs are sometimes utilized to model protein in-
teractions detected with AP-MS because the direct pairwise interactions between the
components of the complexes detected by this technique are generally unknown (Figure
1.2). However, because hypergraph operations are often more challenging computa-
tionally, and because graphs are somewhat more intuitive for manual interpretation,
hypergraphs are not as widely used as network graphs for representing biological re-
lations. Accordingly, complex interaction datasets are often transformed into binary
data. For example, a protein complex detected with AP-MS can be represented as
a set of binary interactions between all components (matrix model decomposition).
Alternatively, since AP-MS involves isolation of complexeses formed around a specific
protein called bait, these complexes can be represented as a set of binary interactions
between the bait and the rest of the complex members called preys (spoke model de-
composition) (Figure 1.2). Nevertheless, both strategies for complex decomposition are
inevitably associated with loss of information about the detected complexes; moreover,
they reportedly generate false positive and/or false negative interactions (9).
1.2.5 Structure of interaction networks
Not only the single elements of interaction networks – the separate physical entities
and their interactions – have been studied extensively during the last decade, but so
has been the overall structure of interaction circuits. Seminal studies (many of which
are reviewed in (2, 14)) have shown with graph-theoretical measurements that such
networks, like many other types of real-world networks, are highly structured.
For example, certain local patterns of interconnections between nodes, called net-
work motifs, are found significantly more often in real-world networks than expected
by chance (5, 115). In the biological context, such motifs are suggested to reflect uni-
versal biological functions: For instance, feedback and feed-forward loops abundant in
8
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gene regulatory networks are proposed to act as amplifiers or filters of biological signals
(112, 132).
Many biological networks show characteristic organization not only on the local,
but also on the global level. Among the most extensively studied properties is the
connectivity of network nodes. The connectivity, or degree, of a node is defined as the
number of counterparts it is connected with in the network. For several types of bio-
logical networks, including metabolic (86) and protein-protein (87) interaction circuits,
node degree has been shown to follow a power-law distribution: P (X = k) = k−γ ,
where k denotes the degree and γ is a constant. This means that the vast majority
of nodes in such networks have a small number of interaction partners, while there
are a small number of so-called ‘hubs’ that have many interaction partners. Due to
the absence of a characteristic node degree, or scale, in such networks, they are called
scale-free (13). The emergence of the scale-free property in interaction webs is suggest-
edly associated with the cell’s tolerance to random errors such as gene mutations (3).
Another common property of many biological circuits that arises from their scale-free
nature is the small-world effect (13, 51, 175). It is essentially associated with very short
average numbers of interactions separating pairs of nodes, and could be a factor aiding
fast reactions of the cell to stimuli (14, 51). The small-world property of a network is
often quantified with the average shortest path length, defined as the average number
of edges one has to follow in order to reach one node starting from another. A related
measure is the network diameter, which is defined as the maximum of all shortest paths
between pairs of nodes. A further phenomenon seen in interaction networks is that the
set of direct network neighbors of a node share more interactions between each other
than expected by chance (that is, network neighborhoods of nodes are more densely
connected than expected by chance). It is traditionally quantified with the clustering
coefficient, defined for each node as the fraction of existing links among its network
neighbors from the number of all possible links among them (175). In other words, for
a node with n network neighbors (node degree = n) among which k edges exist, the





= 2k/n(n− 1). A high average clustering coefficient
is an indicator of the network’s modular structure, since interactions form densely con-
nected communities, or modules. Furthermore, it has been shown that modularity in
biological networks is often organized in a hierarchical manner, leading to the concept
9
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of ‘network of networks’ – that is, nodes connect to form modules, modules connect to
form higher-level network structures, and so on (127, 128).
The bottom line from studies analysing global as well as local properties of interac-
tion networks is that the topology of these networks is far from random. Rather, the
high degree of internal order that governs the cell’s molecular organization is consis-
tently reflected in the networks’ architecture (14).
1.3 Interactions and pathways in aid of expression data
analysis
Interaction knowledge can be exploited in many ways and contexts. To give some
examples: First, manual inspection of the circuitry of certain genes can provide clues
about why a biological process develops as it does and how gene disruptions (such as
mutations, or applied drugs) may lead to a certain phenotype. Second, the functions of a
protein can be predicted based on the interaction network neighborhood of that protein
(146). Third, interaction networks are routinely used as the basis of mathematical
models aiming to simulate and predict the systems-level behavior of biological systems
(99). Fourth, large-scale interaction data and manually curated pathway models are
increasingly applied as a basis for interpreting whole-genome expression data.
1.3.1 Whole-genome expression profiling
Gene expression profiling involves techniques that measure the expression levels of
many genes simultaneously. It is often used to assess the gene expression response of a
biological system to external or internal stimuli like environmental factors or disease.
Such stimuli often provoke changes in the expression of many genes, reflected by al-
terations in the according messenger-RNA concentrations, and ultimately by changes
in the concentration of the protein products of those genes in the biological system.
While protein concentrations are relatively difficult to measure on a large scale, the
abundance of tens of thousands of messenger-RNA molecule types can be easily de-
termined simultaneously. This is usually done with hybridization- or sequencing-based
techniques, such as microarrays or RNA-seq (139, 174). An expression profile of a cell
or a tissue obtained by such techniques is a unique snapshot of the expression activity
of thousands of genes. Using statistical tests, expression profiles of an experimental
10
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condition of interest are typically compared to expression profiles of a control pheno-
type to highlight a list of genes that show significant change of expression between the
two phenotypes (24). For example, if the phenotype of interest is a disease, the genes
that are differentially expressed compared to the control are typically considered to be
related to the disease and could be effective or even causative of it. The list of genes dif-
ferentially expressed in a disease is commonly termed the gene signature of the disease.
Gene expression profiling has an enormous potential in molecular medicine as it can aid
diagnosis by pointing to new, or assessing the expression of known disease biomarkers,
and can help generate hypotheses about potential drug targets and therapies.
1.3.2 Integration of expression data with interaction and pathway
knowledge
A major concern is that gene signatures found by different studies analyzing the same
phenotypic condition are often barely overlapping (47). The lack of agreement may
arise from differences in the experimental techniques and settings used in the accord-
ing studies. Mainly, however, it is attributed to the inherent variability of biological
systems including variations in the genetic background, environmental effects, tissue
heterogeneity, etc. A more concrete hypothesis in the context of disease phenotypes
such as cancer is that changes in the expression of genes causing the disease may be
subtle compared to expression changes of the downstream effectors, which can vary
largely from patient to patient (32, 47, 164). In this context, it is of highest interest
that the coherence across different expression measurements of the same phenotype is
often found to be significantly higher at the level of interaction subnetworks and path-
ways (33, 40, 80). This is primarily because changes in biochemical pathways leading
to certain phenotypic conditions such as disease can often arise from a range of different
alterations in the genes participating in these pathways (65, 118). Beside the better re-
producibility, a further advantage of a pathway-centric perspective on expression data
over the gene-centric one is that pathways provide a better mechanistic insight into
the molecular mechanisms of disease. Last but not least, pathways and sub-networks
may contain genes that play a major role in disease but are not captured through dif-
ferential expression analysis. For example, a gene that is not differentially expressed
but functionally interconnects many counterparts showing differential expression may
11
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be causative of their dysregulation because mutations of the central gene may be dis-
rupting its regulatory relations with its counterparts. Thus, adding a pathway layer
to expression profiles can aid the discovery of molecular processes leading to complex
diseases and of genes that may cause them.
1.4 Aims and organization of the thesis
A major goal of systems biology is the integration of available biological knowledge
within and between different levels like gene expression, biomolecular interactions, etc.
to obtain a better understanding of cellular processes. This thesis addresses three
connected problems in contemporary systems biology research: 1) Current interaction
knowledge is dispersed across hundreds of heterogeneous, complementary databases,
which hampers a system-level view on biomolecular relationships in the cell; 2) Cur-
rent physical interactome maps (in particular integrated interaction data) contain many
false positives that may lead to the generation of false hypotheses in interaction-based
research; 3) Gene signatures are often insufficient for understanding the causes and
molecular mechanisms of complex diseases, without taking into account the relation-
ships between genes. These key points are addressed in the next three chapters, followed
by a general conclusion.
Interaction data integration. Chapter 2 provides a solution to the problem that
current biomolecular interaction knowledge is scattered in hundreds of heterogeneous
and complementary databases, hampering a system-level view on human cellular biol-
ogy. We have designed and developed ConsensusPathDB (89, 92), an interaction meta-
database aiming to integrate the interactome pieces together into a seamless network
comprising different types of relations between physical entities. ConsensusPathDB
collates multiple functional aspects of human genes like protein interactions, cataly-
sis, signal transduction, and gene regulation, yielding a more complete and less biased
picture of cellular processes than the separate interaction resources. In Chapter 2,
we outline the design and content of the meta-database as well as its web interface
offering many ways to exploit the integrated network, for instance in the context of
gene expression data. The necessity of data integration is demonstrated with several
examples.
12
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Confidence scoring of protein interactions. Chapter 3 tackles the problem
that current protein-protein interaction data often contain considerable amounts of
false positives. We propose a novel, non-parametric interaction confidence assessment
approach called CAPPIC (91). It exploits solely network topology and does not depend
on any reference sets or additional knowledge about the network’s elements. Because
such reference sets and additional information are not always available or may be am-
biguous, they are a limiting factor for other interaction confidence assignment meth-
ods relying on them. We assess the performance of CAPPIC on a comprehensive set
of yeast interaction networks in comparison with other topology-based methods, and
demonstrate that CAPPIC reliably estimates interaction confidence and outperforms
those methods. CAPPIC is used to assign confidence scores to the protein-protein in-
teractions in ConsensusPathDB, which serve for distinguishing a high-quality physical
interaction network.
Disease gene and pathway identification. Chapter 4 addresses the concept of
integrating expression data with interaction or pathway knowledge to derive hypotheses
about the molecular causes and mechanisms of disease. In this context, we propose the
use of unbiased functional gene sets based on neighborhood of genes in the integrated
interaction network. Notably, the underlying network is a result from the combination
of interaction data integration (as per Chapter 2) and interaction confidence-based
filtering (as per Chapter 3). The resulting gene sets can be used complementarily
to curated pathways for pathway-driven expression data interpretation, and overcome
several problems faced by the traditionally used manual pathway definitions. With
two examples we show that the combination of collating heterogeneous interaction
data, interaction de-noising, and integration of interaction and expression data could
be paramount for unveiling genes causative of complex diseases such as cancer.
Further in Chapter 4 we show how integrating metabolomics data with transcrip-
tomics/proteomics data on the level of pathways can help to generate novel hypotheses
about biological processes related to a phenotype (23), and present the first available
computational tool for this purpose (90). Such integration is motivated by the fact that
complex diseases like cancer impact not only gene expression but also other, equally
important aspects of the living cell like metabolism (77). Now that data are being
generated on the large scale at several levels like gene expression, metabolism, and
interaction, the time for large-scale integration of these data has come.
13
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In summary, the key findings of the thesis are:
• design and development of the recognized interaction meta-database Consensus-
PathDB (89, 92) that collates different types of interactions from currently over
twenty resources into a seamless interaction network of unprecedented coverage;
• development of a novel tool for evidence mining and novelty assessment of protein-
protein interactions (122);
• development of a novel, network topology-based method called CAPPIC for as-
sessing the confidence of binary interactions (91);
• application of the integrated and de-noised human interactome map in a new
approach for the identification of disease-causing genes;
• development of a novel tool for the joint analysis of large-scale transcriptomics





Currently, a systems view on molecular biology of the cell is severely hampered by
the way interaction data are handled. The available interaction knowledge is dispersed
across hundreds of databases, each of which has a specific interaction type focus, detail
level, and data model and supports a different subset of the available data exchange
formats. Most databases are focused on a single type of functional relations between
biomolecules, while in reality, biological processes comprise many different types of in-
teractions. Furthermore, even databases specialized on the same interaction types are
often complementary than overlapping (35, 41). We designed and developed an interac-
tion integration database called ConsensusPathDB (89, 92) to address these problems
and close the gap between insular interaction data repositories. ConsensusPathDB
collates the pieces of the human interactome puzzle found in these repositories into
a seamless network to create a more complete snapshot of the interactions that take
place in the cell. With approximately 160,000 unique interactions of different type
obtained by the integration of currently 26 interaction and pathway resources, Consen-
susPathDB represents the most comprehensive human interactome map available. This
chapter deals with the design and content of the ConsensusPathDB meta-database, as
well as its interfaces enabling researchers to exploit the integrated data in different
contexts via the world wide web. While ConsensusPathDB instances exist also for the
model organisms mouse and yeast, only the human instance will be referred to in this
chapter.
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2.1 Introduction to interaction databases
The Pathguide pathway resource list – a comprehensive catalogue of existing interaction
and pathway repositories (11) – currently lists 325 different interation databases divided
into several categories according to their content type (protein-protein interactions,
metabolic reactions, gene regulation, etc.). Most of them are primary data resources
that collect interactions directly from the literature or through manual data submis-
sions. Since it has been recognized that primary databases are rather complementary
to each other (41), efforts are made to improve the communication between their de-
velopers and unify interaction curation rules and content (117). Furthermore, standard
formats have been defined for interaction data exchange (154). Several meta-databases
have emerged that combine interactions from several primary resources. Examples
include UniHI (28), MiMI (161) and I2D (20). Nevertheless, many of these standard-
ization efforts and meta-databases are still limited to a single interaction type (for the
above examples the focus is at protein-protein interactions). STRING (159) integrates
a number of different functional associations among genes including gene neighborhood
on the DNA, gene fusion, compartment co-occurrence, co-expression, co-analysis in
experiments, co-occurence in databases, co-citation, physical interaction of the prod-
ucts, and interaction homology. These association evidence channels are combined to
a joint interaction score for gene pairs. Pathway Commons (26) is a common query
interface to nine interaction databases that extracts interactions through standard data
formats and provides interaction and pathway search functionalities. To broaden the
magnitude of interaction data integration in terms of the number of different types of
interactions, number of integrated resources, and data integration depth, we created
the meta-database ConsensusPathDB. Currently, it contains data from twenty-six of
the most popular primary resources for direct protein-protein interactions, metabolic
and signaling reactions, and gene regulation (termed source databases; Table 2.1). The
number of integrated databases grows by approximately one new database per release
(Appendix Figure A.1).
Ten of these resources contribute biochemical reactions. Only two of them, Re-
actome (39) and INOH (http://www.inoh.org), contain both signaling and metabolic
reactions. The rest are focused only on metabolism (HumanCyc (131) and the Edin-
burgh Human Metabolic Network Reconstruction - EHMN (108)), or only on signaling
16




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2. TOWARD MORE COMPLETE INTERACTOME MAPS
(Pathway Interaction Database - PID (138), Signaling Pathway Integrated Knowledge
Engine - SPIKE (121), BioCarta (http://www.biocarta.com/genes/index.asp), Net-
Path (93) and InnateDB (107)). The Kyoto Encyclopedia of Genes and Genomes -
KEGG (95) is a repository for manually drawn pathway diagrams of both signaling
and metabolic pathways; however, computer-readable reaction data is available only
for the metabolic but not for the signaling pathways. Most of these ten databases
are general-purpose repositories, that is, they attempt to chart the molecular reaction
mechanisms of a palette of biological processes. Exceptions are InnateDB, which fo-
cuses on interactions involved in the innate immune response to microbial infection,
and NetPath, which catalogues immune and cancer signaling pathways. Common to
all biochemical reaction databases is that they are subject to manual curation. Some of
the databases (e.g. HumanCyc) have resulted from computational reaction predictions
and are moderately curated, while others (e.g. Reactome, SPIKE, PID) store highly
curated reaction data that are most often manually extracted from the scientific lit-
erature by experts. Furthermore, the different databases provide a different level of
annotation detail of the contained interactions. For instance, compartment annotation
of reactions and information on post-translational modifications of their participants is
available only in Reactome, INOH, PID, BioCarta, and NetPath. In almost all of the
reaction databases mentioned here, the contained reactions are organized into groups
representing biochemical pathways (Table 2.1).
Four of the databases mentioned above contain gene regulatory interactions; these
are SPIKE, PID, BioCarta, and InnateDB. Publicly accessible gene regulatory data
are still relatively sparse for human, thus these databases provide only a small number
(in the order of a few hundred to a few thousand) of gene regulatory relations mined
manually from the scientific literature.
Twelve of the databases integrated in ConsensusPathDB focus only on physical
protein interactions. These include IntAct (7), Database of Interacting Proteins (DIP)
(136), Molecular Interaction Database (MINT) (25), Human Protein Reference Database
(HPRD) (98), Comprehensive Resource of Mammalian protein complexes (CORUM)
(134), Biological General Repository for Interaction Datasets (BioGRID) (149), Mam-
malian Protein-Protein Interaction Database of the Munich Information Center for
Protein Sequences (MIPS-MPPI) (119), Biomolecular Interaction Network Database
(BIND) (83), Pathogen Interaction Gateway (PIG) (46), PhosphoPoint (179), PDZbase
18
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(16), and MatrixDB (29). Data in most of these repositories are typically collected from
the literature through text mining followed by manual curation to some extent, or are
directly submitted by experimentalists. Some of the databases have a particular focus
on interactions between certain types of proteins or taking place in specific compart-
ments. For example, PhosphoPoint focuses on interactions of human kinases, PDZbase
on interactions involving PDZ domains, and MatrixDB comprises interactions between
extracellular proteins and polysaccharides on the cell surface. Similarly, the Pathogen
Interaction Gateway imports interactions between human and pathogenic proteins from
other databases like IntAct. The rest of the protein-protein interaction repositories
integrated in ConsensusPathDB are general-purpose databases aiming to assemble a
protein interactome map of human as well as of other species. Some of the protein in-
teraction databases (like IntAct, DIP, and MINT) contain interactions involving more
than two proteins (complex interactions), while others (like BioGRID and PIG) contain
only binary interaction data. Some of the databases (e.g. IntAct) provide information
on the modification state of interactors. This feature is particularly important as some
interactions are modification-dependent, that is, they take place only if the proteins
are post-translationally modified (which is often the case with interactions building up
signaling cascades). Apart from the data extracted from the protein interaction-focused
databases, we have explicitly defined protein interactions based on the composition of
protein complexes found in some of the biochemical reaction databases. Furthermore,
many physical interactions are provided by the signaling database SPIKE.
Pathway annotation of the bulk of available protein-protein interactions is still forth-
coming. In contrast, most of the resources for biochemical reactions annotate all or
most of the reactions to biochemical pathways as mentioned above. Several further
pathway resources exist that do not provide information about pathway constitution in
terms of reactions but instead depict pathways in manually drawn diagrams and list the
genes participating in each pathway. Such resources provide valuable information which
can be used in approaches for pathway-level analysis of gene expression data (discussed
in Chapter 4). Such pathway databases integrated in ConsensusPathDB are Pharma-
cogenomics Knowledge Base - PharmGKB (163), Small Molecule Pathway Database -
SMPDB (57), WikiPathways (125), Signalink (102), and the signaling pathway domain
of KEGG.
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2.2 Data model of ConsensusPathDB and data integra-
tion
2.2.1 Database structure
Developing a meta-database that holds information on interactions of different nature
and annotated in a different level of detail by the source databases required a design
of an adequate database schema. The schema had to be general enough to allow for
representing interactions of different nature, and at the same time specific enough
so that interaction details such as cellular location could be included, if available.
Moreover, the schema design had to consider the fact that interaction datasets are
overlapping to some extent, and had to offer an adequate way to identify overlapping
information and avoid redundancy.
The design of the data repository of ConsensusPathDB follows a bipartite multi-
graph interaction data model (Figure 2.1), which enables it to acommodate molecular
relations with arbitrary cardinality. Its central classes are PhysicalEntity, Interaction
and Edge. Physical entities and interactions are accordingly the two different types
of nodes in the bipartite graph model and are connected by edges denoting the par-
ticipation of entities in interactions. There are currently three types of interactions
represented by three distinct classes that inherit from the general Interaction class:
physicalInteraction, biochemicalReaction (representing both metabolic and signaling
reactions), and geneRegulation. Each physical entity has a type as well, which is either
gene, messenger RNA (mRNA), non-coding RNA (ncRNA), peptide, protein, protein
complex, family (gene or protein family), compound/metabolite, or unknown type.
Physical entities are accommodated in ConsensusPathDB in a basic form – for exam-
ple, physical entities of the type protein do not have post-translational modifications by
themselves. Instead, edges linking physical entites to their interactions are the carriers
of information about the state (such as post-translational modifications or mutations),
the cellular compartment location, as well as stoichiometry information of the interac-
tion participant in the interaction. Each edge records the role of the physical entity
in the interaction (such as product, substrate, enzyme, physical interactor, regulated
gene, enhancer or inhibitor). Physical entities are organized hierarchically (accom-
plished through the relation has component, Figure 2.1), which is necessary for repre-
senting protein complexes and gene families in terms of their composition. Interactions
20
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Figure 2.1: Entity-relationship diagram visualizing the structure of the Consen-
susPathDB interaction meta-database. The names of classes (rectangles) which are
members of the generic DBobject (database object) class are capitalized (the correspond-
ing ‘is-a’ relationships are omitted for better visualization). The numbers correspond to
relationship cardinalities. The central classes are Entity (representing physical entities like
genes, proteins, complexes, metabolites, etc.), Interaction (representing interactions), and
Edge (connecting entities with their interactions). The schema follows a bipartite graph
model for representing interactions, to allow representation of biomolecular relationships
of arbitrary cardinality. The cluster,clustS, clustM, clustL, and clustV attributes of Inter-
action serve for indicating which interactions are similar regarding the entity composition
and have matching stoichiometry, modification, location, and mutation patterns of the
entities (see main text).
21
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can be organized in pathways (instances of class Pathway which link to Interaction via
has interaction, Figure 2.1). Similarly to physical entities, pathways are organized in a
hierarchical manner (a pathway may consist of sub-pathways: relation has subpathway,
Figure 2.1). Many further relations exist in the database schema for storing additional
data, including kinetics information (including kinetics laws and parameter values),
details on mutations (site and mutation type) or modifications (residue and chemi-
cal group) (Figure 2.1). The relational schema described here was implemented as a
PostgreSQL database system.
2.2.2 Integration of interaction data from multiple sources
The task of interaction data integration is hindered primarily by the heterogeneity re-
garding the data formats of currently available interaction resources. We retrieve the
data from source databases in different ways and formats, ranging from files in stan-
dard interaction exchange formats including BioPAX, PSI-MI, and SBML to database-
specific XML or tab-delimited files, Excel tables, MySQL or PostgreSQL database
dumps, or SOAP web services. Table 2.1 provides information about how interaction
data were retrieved from each source database. We created a separate data adapter for
each database that extracts its content and translates it in compliance with the data
model of ConsensusPathDB. The data are then not simply stored in the repository of
ConsensusPathDB, but also compared to the information already present in it to detect
similarities and consequently avoid redundancy. Simple physical entities are compared
to each other based on identifiers from a unified namespace, called primary identifiers.
These identifiers are UniProt (6) for proteins, Ensembl (53) for genes, and KEGG
(or ChEBI (42), in case that a KEGG identifier is missing) for metabolites, because
these databases annotate very extensively human proteins, genes and metabolites, re-
spectively. We attempt to map all identifiers provided for every entity by the accorging
interaction resources to one or more primary identifiers. For this purpose we created an
identifier cross-map by parsing and extracting acession number mappings from eight
genomic, proteomic, and metabolite databases including UniProt, Ensembl, Entrez
(109), HUGO Gene Nomenclature Committee (HGNC) (142), Human Protein Refer-
ence Database (HPRD), KEGG, ChEBI and Human Metabolome Database (HMDB)
(177). Simple physical entities whose set of primary identifiers match, or complex en-
tities such as protein complexes or families with matching composition, are considered
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identical and are merged in ConsensusPathDB. Annotation of merged physical enti-
ties such as external identifiers, literature references, and synonyms are stored in a
complementary manner.
Interactions from different sources are also compared to each other. Biochemical
reactions with matching substrates and products, physical interactions with matching
interactors, as well as gene regulatory interactions with matching regulated gene are
considered similar. Notably, similar interactions may differ in the modification state,
location, or stoichiometry of their participants. For example, as mentioned above, the
Reactome database provides information about the modification state and subcellular
location of each interacting entity, whereas KEGG does not. To enable the comparison
of interactions from databases with such differences in the annotation detail, we apply
the following strategy: Each interaction is stored separately in ConsensusPathDB, and
similar interactions (as defined above) are marked as similar. This is accomplished
through equal settings of the ‘cluster’ attribute of the Interaction class (Figure 2.1) for
similar interactions. It should be noted that in this context, the word ‘cluster’ denotes
a group of interactions that have identical composition in terms of substrates and
products (for biochemical reactions), physical interactors (for protein interactions) and
regulated gene (in the case of gene regulatory interactions) and is not to be confused
with graph clusters, for example. Interactions within the same ‘cluster’ are divided
into sub-groups depending on whether their stoichiometry, modification, location, and
mutation information match. This is done through settings of the ‘clustS’, ‘clustM’,
‘clustL’, and ‘clustV’ attributes of Interaction. For example, ‘clustM’ has the same value
for interactions in the same ‘cluster’ that match in the post-translational modification
pattern of their protein participants. The decision, which of the similar interactions
are to be considered identical, depends on the concrete application and is therefore left
to the end-user. If, for example, a network of reactions from ConsensusPathDB is to
be used as the basis for models and computer simulations of a biological process, then
interactions in different compartments should probably be differentiated. If, on the
other hand, the aim is to retrieve all functional relationships of specific biomolecules in
the cell, then compartment information is probably irrelevant.
For each object in ConsensusPathDB (including physical entities, interactions and
pathways), we record its sources and source database identifiers to enable linking to the
original data, as well as all literature references where the object is primarily described.
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The data integration module of ConsensusPathDB comprises computer programs
that create an empty repository following the described schema, download the latest
versions of all data from the source databases, translate each dataset into a unified for-
mat consistent with ConsensusPathDB’s data model, integrate the data into the data
repository in a non-redundant manner, and perform post-processing on the integrated
data e.g. to calculate overlap statistics. The integration module is executed fully au-
tomatically every three months to ensure the content of our meta-database is always
up-to-date. Appendix Figure A.1 shows a release timeline summarizing the unique in-
teraction count and integration of new source databases in ConsensusPathDB since its
initial publication.
2.3 A global view on the integrated content of Consen-
susPathDB
ConsensusPathDB is the largest interactome map for Homo sapiens. Currently (Release
20), it comprises 51,564 unique physical entities (32,357 proteins or protein families,
10,252 protein complexes, 120 non-coding RNA molecules, 5,040 metabolites, etc.),
157,461 unique interactions (2,270 gene regulatory interactions, 16,721 biochemical re-
actions, and 138,470 complex or binary protein interactions), as well as 3,161 pathways.
Interaction integration enabled the assessment of the overlaps and differences between
the integrated resources for interaction and pathway data, which we detail below.
2.3.1 Complementarity of interaction data resources
The interaction network in the ConsensusPathDB repository has been obtained by col-
lating a total of 317,065 interactions from the source databases. The fact that the
unique interactions in the integrated network are less than half that number indicates
that the databases do overlap to some extent. We have summarized the pairwise
database overlap sizes both in terms of interactions and physical entities in Table 2.2.
The table essentially shows that the databases are complementary to each other and
none of them is completely contained in another. Each database contributes unique
interactions to the integrated network. The non-zero overlaps between biochemical re-
action and protein interaction repositories is due to the fact that we explicitly defined
protein interactions from protein complexes found in the former, as mentioned above.
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2. TOWARD MORE COMPLETE INTERACTOME MAPS
Figure 2.2: Histogram of the number of database sources per interac-
tion in ConsensusPathDB. The vast majority of interactions (69%) are avail-
able in only one of the integrated databases. Only one interaction has 15 sources
(NFKB1 HUMAN – TF65 HUMAN), two interactions have 14 sources (IF4E HUMAN
– 4EBP1 HUMAN and GRB2 HUMAN – SOS1 HUMAN), and four interactions have
13 sources (CCNB1 HUMAN – CDK1 HUMAN, EGF HUMAN – EGFR HUMAN,
CCNE1 HUMAN – CDK2 HUMAN, and SMAD3 HUMAN – SMAD4 HUMAN); all of
these are physical protein interactions.
We further dissected the interactions in the integrated network according to the num-
ber of different source databases per interaction (Figure 2.2). Strikingly, around 69%
of the interactions are contained in a single source database only, while the fraction
of interactions from exactly two or exactly three source databases is 13% and 9%, re-
spectively. Only one interaction (the physical interaction between the 105p and 65p
subunits of Nuclear factor NF-kappa-B: NFKB1 HUMAN and TF65 HUMAN, respec-
tively) is present in 15 source databases, while no interactions are common to more
than 15 databases.
We exemplarily looked at the distribution of protein interactions of one of the best
annotated proteins, the Tumor suppressor protein p53 (P53 HUMAN), which plays a
central role in the cell cycle and whose mutations are often associated with cell cycle
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dysregulation leading to cancer (75). We found 745 unique protein interactions of p53 in
ConsensusPathDB. Four of the most comprehensive protein interaction databases that
we have integrated – IntAct, HPRD, BioGRID and DIP – contained in total 509 of
these interactions, and only 12 interactions were common to all four databases (Figure
2.3). This finding evidences that the separate databases, even if focused on the same
interaction types, are highly complementary in their interaction content.
Figure 2.3: Overlap and complementarity of in-
teractions of p53 in four major protein interaction
databases. Although p53 is one of the most extensively
analyzed proteins, protein-protein interaction databases
contain complementary subsets of its available interac-
tions as shown in this Venn diagram.
In addition to providing a
more comprehensive view on
each physical entity’s inter-
actions of a given type like
in the above example, Con-
sensusPathDB reveals multi-
ple functional relationships be-
tween the entities at the same
time. For instance, we found
that each human gene/protein
represented in our database is
involved in 1.5 distinct types
of interactions (gene regula-
tory interactions, biochemical
reactions, and protein interac-
tions) on average. The number
is relatively high, considering
the uneven numbers of interactions of each type found in in ConsensusPathDB. For
instance, currently there are 61 times more physical protein interactions than gene
regulatory interactions. If only genes/proteins participating in available gene regula-
tory interactions are considered, the average number of different interaction types per
gene/protein is 2.6. With the elucidation of more regulatory and biochemical gene
relationships in human, an ascending tendency of the number of different interaction
types available for every gene in ConsensusPathDB is expected.
Next, we analyzed the degree of coherence and complementarity of the integrated
source databases beyond the interaction level. Several databases are concerned with
27
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the higher-level organization of interactions in biological processes and attempt to cre-
ate molecular-level models of such processes. The resulting pathway definitions are
extensively used, for example, in methods for pathway-based expression data analysis
(discussed in Chapter 4). We were interested in the level of similarity between path-
way definitions from different databases. For each pathway from each database, we
compared its composition (in terms of physical entities or interactions) to all pathways
from the rest of the source databases. The similarity of a pair of pathways P and Q
was quantified with the Jaccard index, J(P,Q) = |P ∩Q|/|P ∪Q|, where |P ∩Q| is the
size of the intersection and |P ∪Q| is the size of the union of the two pathways in terms
of entities or interactions. J(P,Q) ranges from 0, if P and Q share no items, to 1, if
they completely match regarding their composition. The maximum reached Jaccard
index value per pathway (i.e. the maximum similarity to any pathway from a different
database) is shown for all pathways in Figure 2.4, A) and B) (for physical entities and
interactions, respectively). It is evident that pathways from every database are mostly
unique in their composition. Since most pathway databases attempt to chart exten-
sively studied biological processes such as Apoptosis, TCA cycle or Glycolysis, we were
interested how well the compositions of such pathways match across the databases.
We exemplarily inspected the composition of the Glycolysis pathway according to four
established metabolic pathway databases (Reactome, KEGG, HumanCyc and INOH).
The pathway was present as “Glycolysis” in Reactome, “Glycolysis and gluconeoge-
nesis” in INOH, “Glycolysis and gluconeogenesis” in KEGG, and “Glycolysis I” in
HumanCyc. We found astonishing differences in the pathway composition across the
four databases (Figure 2.4 C) and D) show their overlaps in terms of physical entities
and interactions, respectively). For example, the INOH Glycolysis and gluconeogen-
esis instance contained 21 reactions involving a total of 45 distinct physical entities,
while the homonymous KEGG instance consisted of 33 reactions and 65 entities. The
overlap between all four databases comprised only 3 reactions or 17 entities (Figure 2.4
C) and D)). Results were similar for the comparably well-studied Apoptosis and TCA
cycle pathways (not shown), indicating that pathway definitions are rather a matter of
subjective judgment as pathway boundaries are generally unclear (169).
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Figure 2.4: Overlap of pathway composition across databases. A and B: His-
tograms of the similarity (maximum Jaccard index) of pathways to counterparts from
other databases in terms of physical entity composition (A) or interaction composition
(B); C and D: comparison of the composition of the Glycolysis pathway in terms of phys-
ical entities C or interactions D across four major pathway databases.
2.3.2 Topological properties of the human protein interaction network
In the previous chapter we mentioned several network metrics that can be applied to
characterize the structure of real-world networks. Such metrics are commonly used
to derive hypotheses about the organization and evolution of functional associations
of biomolecules within the cell, and are often directly related with biological phenom-
ena (14). Because of the compositional differences of current interaction databases,
however, topological analyses hide the risk of bias in the results depending on which
database analyses are based on. We utilized the binary protein-protein interaction net-
work from ConsensusPathDB, as well as the separate contributing source databases, to
spot common as well as specific network structural properties. Interactions with more
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than two participants were disregarded in this analysis. We modeled each interaction
dataset as an undirected graph where nodes represented proteins and edges represented
their interactions. The graphs were characterized in terms of the topological measures
introduced in the previous Chapter (Table 2.3). Notably, the networks had different
coverage of the human physical interactome, ranging from around 100 (MatrixDB)
to over 96,000 (ConsensusPathDB) interactions. The average shortest path spanned
around 4 interactions, and the diameter ranged between 8 and 17. This demonstrates
that all networks in the analysis are the small-world, suggesting that the property is
often preserved in samples of the real human physical interactome barely dependent on
their size. On the other hand, the range of the average clustering coefficient across the
analyzed networks was fairly big: For the large-scale dataset from IntAct (IntAct-LS)
it measured only 0.05, which was more than five times smaller than for BIND (clus-
tering coefficient = 0.26). IntAct-LS and BIND seem to represent different subsets of
the interactome that are barely overlapping: Table 2.2 shows that they have only 133
interactions in common. While IntAct-LS consists of the large-scale experimental data
published by Rual et al. (133), Stelzl et al. (152), and Ewing et al. (50), BIND com-
prises mostly small-scale experimental data manually curated from the literature. The
clustering coefficient of the integrated network lied between the two extremes (cluster-
ing coefficient = 0.16). The average node degree ranged from less than 2 (CORUM and
MIPS-MPPI) to 13.3 (ConsensusPathDB) interaction partners per protein. Overall,
the results confirmed that conclusions about the topological properties of the human
interactome may differ according to which database is used as a basis for the analysis.
The distributions of protein degree and clustering coefficient in the integrated hu-
man physical interactome map are shown in Figure 2.5. The evident power-law distri-
bution of protein degree, approximated by P (X = k) ∼ k−1.42 (where k denotes protein
degree) indicates the scale-free nature of the network (13). The power-law scaling of
the clustering coefficient with protein degree obvious in Figure 2.5 is a direct evidence
for a hierarchical organization of modularity in the network (127, 128).
2.4 Interfaces of ConsensusPathDB
To grant researchers around the globe access to the integrated content of Consensus-
PahDB, we have developed a web interface and a specialized plugin for the popular
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2. TOWARD MORE COMPLETE INTERACTOME MAPS
Figure 2.5: Distributions of protein degree and clustering coefficient in the
integrated human physical interactome map. The number of proteins (blue line,
left-hand-side y-axis) and the clustering coefficients of proteins (red line, right-hand-side
y-axis) are plotted against protein degree.
network analysis and visualization software tool Cytoscape (148).
2.4.1 The ConsensusPathDB web interface
The web interface of ConsensusPathDB can be accessed with a contemporary web
browser at http://cpdb.molgen.mpg.de. Its functionality is summarized in Figure 2.6
and is extensively documented in an online manual found on the ConsensusPathDB
home page. The web interface offers possibilities to query the interactions of specific
physical entities or pathways, or search for shortest interaction paths connecting pairs
of biomolecules. Selected interactions can be visualized either in an image-based or a
Java-applet-based visualization framework. Both frameworks represent interactions in
an identical way. Interactions are displayed as directed bipartite multigraphs where
circular nodes represent interactions and rectangular nodes represent physical entities
(Figure 2.6). The color of each node encodes the type of the according interaction
or entity. Entities are linked to their interactions with edges whose line style, arrow
shape and orientation encode the roles of the entities in the interactions. The color
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Figure 2.6: Overview of the funtionality of the ConsensusPathDB web inter-
face. By either searching for interactions of specific physical entities or pathways, searching
for shortest interaction paths connecting two physical entities, upload of expression data
for gene set-based analysis, or upload of standard files containing interactions which are
matched to the meta-database, custom interaction networks can be constructed and dis-
played in one of ConsensusPathDB’s visualization environments. Consistent with the data
model of the database, these networks are visualized as bipartite multigraphs where one
class of nodes (shown as rectangles) represent physical entities, and the other class (shown
as circles) represent their interactions. Node color shows the type of the corresponding
physical entity (gene, protein, metabolite, etc.) or interaction (gene regulation, protein
interaction, or biochemical reaction). Edges connect physical entities to their interactions;
edge style denotes the role of the entity (regulated gene, transcription factor, physical
interactor, reaction substrate, etc.) and edge color shows the source of the interaction.
of edges encodes the database source of the interaction. Multiple edges with different
styles denote that an entity has multiple roles in the interaction (e.g. in gene regulatory
self-interactions, the protein product will also serve as a transcription factor in the inter-
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action). Multiple edges of different color, on the other hand, show that the interaction
is present in multiple source databases. Figure 2.6 shows as an example a connected
interaction network comprising one gene regulatory interaction, three physical interac-
tions, and two biochemical reactions, originating from different source databases. The
depicted interactions involve one gene, several proteins and protein complexes, and one
compound molecule. The visualization frameworks of the ConsensusPathDB web inter-
face allow interactive operations on the displayed networks, such as interaction removal,
node expansion, node location, etc. While the Java-applet-based framework requires a
Java Runtime Environment to be installed on the client computer and has higher pro-
cessor and RAM requirements to the client computer than a simple computer image, it
has several advantages, especially when it comes to visualizing larger networks. Network
nodes (physical entities/interactions) are movable and can be rearranged automatically
using different layout methods. Network viewing is further facilitated through a zoom
function. Most notably, in the Java-applet-based visualization environment, custom
numerical values (e.g. gene/protein expression data) can be overlaid on the displayed
network. The values are shown in a red-green color gradient on the according physical
entity nodes. This feature aims to enable the visual interpretation of numerical data
in the context of interaction sub-networks from ConsensusPathDB such as manually
curated pathways or user-generated sub-networks. Any network displayed in the vi-
sualization frameworks of ConsensusPathDB can be downloaded in BioPAX format or
as a computer image. Moreover, the protein interaction part of the ConsensusPathDB
network is available for download through the web page in PSI-MI and tab-delimited
formats.
Apart from interaction querying and visualization, the web interface offers the
possibility to verify pathway models and extend them in the context of the Consen-
susPathDB content. Users can upload interaction networks in BioPAX, PSI-MI or
SBML formats. Upon upload, the interactions are matched to the content of the meta-
database, and are displayed along with their similar counterparts from the integrated
source databases. This aids the identification of spurious interactions in the uploaded
models, and easily shows evidence for each interaction from the dozens of integrated
databases. The uploaded interactions and entities are enriched with annotation from
the meta-database such as publications, synonym names, and database identifiers. No-
tably, the network can be extended by expanding its physical entities with further
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interactions from the integrated repository, and downloaded for use with other soft-
ware.
In the primary focus of the web interface of ConsensusPathDB are tools for interaction-
and pathway-based analysis of transcriptomics or proteomics data. Such data can be
uploaded either as a summary list comprising e.g. differentially expressed genes, or in
the form of numerical values for every measured gene/protein. Over-representation and
enrichment analyses can be carried out with these data based on predefined pathways,
sub-networks, and Gene Ontology (8) categories residing in the meta-database. The
goal of these functionalities is to identify pathways and hot-spots in the integrated net-
work which exhibit a changed activity in the phenotype of interest. Results can help
to unveil the molecular mechanisms leading to these phenotypes and to suggest novel
phenotype-associated genes. The underlying approaches are detailed in Chapter 4.
2.4.2 The ConsensusPathDB plugin for Cytoscape
As mentioned in the previous chapter, protein-protein interactions can already be de-
tected on a large scale, owing to the development of a multitude of biological and
computational techniques for this purpose. After generating a network of detected or
predicted interactions, one usually faces the task to collect evidence for every interaction
from the literature, and to identify interactions that have not been published previously.
This information is useful in order to estimate the performance of the interaction screen,
and to assess the contribution of its results toward the completion of the protein-protein
interaction map of the species under study. To accomplish this task, one typically has
to search the new data against every single protein-protein interaction repository. Even
more tedious is the manual mining for interactions in the scientific literature in order
to collect the publication references and different detection methods for each detected
or predicted interaction. Apart from that, the number of publications reporting an
interaction is an often desired interaction attribute when dealing with protein-protein
interaction networks, since it is a direct evidence for interaction veracity (114). To
aid the process of interaction evidence mining, we have developed a ConsensusPathDB
plugin for Cytoscape (122). Our plugin searches all interactions from a network loaded
in Cytoscape against the interaction space of ConsensusPathDB through dedicated web
services. Interactions that are not present in any of the integrated resources are high-
lighted, since they constitute either novel or false positive interaction predictions, likely
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Figure 2.7: Overview of the funtionality of the ConsensusPathDB plugin for
Cytoscape. A Menu screen of the plugin; B the ConsensusPathDB custom visual style
where interactions with database evidence are black and weighted by the number of pub-
lications, while novel interactions are shown in green; C newly imported attributes of a
selected interaction are shown in the ‘Interaction details’ tab of Cytoscape’s results panel;
D evidence mining time plot for networks of different size with default parameters (for this
performance assessment, all query interactions were present in ConsensusPathDB such
that the mining process took maximal time). The sizes of the networks predicted using
large-scale interaction screening by Rual et al. (133) [R], Stelzl et al. (152) [S] and Ewing
et al. (50) [E] are marked on the x-axis for a reference.
necessitating confirmation with complementary techniques. For the rest of the inter-
actions, literature evidence (in the form of PubMed identifiers), interaction detection
methods, interaction database references, and pathway co-ocurrence of interactors are
extracted from our meta-database and can be viewed in Cytoscape. From there, these
data can be exported as interaction attribute files. The plugin can be used also to spot
interactions that have been missed in the screen (i.e., false negatives) by applying it
on the complement of the interaction graph (which comprises all possible protein pairs
that are not contained in the network). The ConsensusPathDB plugin-in is available
through Cytoscape’s plugin manager. Its functionality is summarized in Figure 2.7.
2.5 Discussion
Through the collation of dozens of publicly available interaction resources, we have
created ConsensusPathDB: the most comprehensive interactome map available for hu-
man and for the model organisms mouse and yeast. Data integration enabled us to
assess the similarities and differences between the separate resources. We found grave
discrepancies regarding the interaction content of these resources even for well-studied
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proteins and pathways. Our findings strongly advise against limiting to a single pri-
mary dataset in interaction- and pathway-based research, because the outcome of such
analyses would be highly dependent on the particular interaction database employed.
Integrated interaction data should be used instead, as they represent biological reality
in a more comprehensive and unbiased way (35).
The interaction content of ConsensusPathDB can be used in many ways and con-
texts. 1) It offers a basis for analyses of the global and local topological properties
of the human interactome. 2) It provides molecular models of biological processes for
computational simulations. 3) It serves as a centralized repository for curated pathway
models for pathway-driven analyses of expression data. 4) It can be used as a common
interaction query interface for many databases. 5) It easily shows content overlap and
discrepancies across databases, pointing molecular biologists to those best suited for
their specific research, and helping database developers to spot and amend data er-
rors. 6) Since it additionally includes many physical interactions between human and
pathogenic proteins, it can serve as an explanatory basis for infectious diseases. There
are many more application areas of ConsensusPathDB that are not mentioned here.
In Chapter 4 we describe its applications in the context of gene expression data for
identifying causative genes and interaction communities related with complex diseases
such as cancer.
Although ConsensusPathDB contains several major types of direct interactions be-
tween biomolecules, there are further functional relation classes that are not yet inte-
grated. An example are genetic interactions, referring to a phenomenon in which two or
more mutations in different genes have an effect on the phenotype that is different than
expected from the individual mutations (38). With the increasing generation of such
data in human, a natural extension to ConsensusPathDB would be to integrate genetic
interactions into the interactome map. Due to the generic design of the database, such
an extension is in no way challenging. In fact, we have already integrated the DRYGIN
yeast genetic interaction database (101) into the yeast instance of ConsensusPathDB
that will be visible in the next database release.
Notably, all integrated interaction datasets are treated equally in ConsensusPathDB
(that is, they are imported without any filtering), albeit in reality the separate datasets
are of different quality. Due to the considerable manual curation efforts that have been
applied to generate the currently integrated metabolic, signaling, and gene regulatory
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interaction data, these data are much less error-prone than large-scale protein interac-
tion data (72, 105). One way to deal with the high level of false positive protein-protein
interactions is to consider the number of methods each interaction has been detected
with, as suggested by von Mering et al. (114). Because literature evidences for in-
teractions in ConsensusPathDB are assembled from many databases, their number is
certainly a more reliable interaction confidence measure than the according numbers in
the separate databases. However, in the next Chapter we argue that literature evidence
is not an optimal criterion for interaction confidence because interactions with weaker
literature evidence are not necessarily false. As a more elegant solution, we propose a
novel interaction confidence scoring method. With that method we have calculated a
confidence value for each binary protein-protein interaction in ConsensusPathDB. The
resulting confidence scores are provided in the downloadable protein interaction data
and are shown in the interaction visualization frameworks. The confidence score can
be used as a criterion for interaction filtering, or can be treated as interaction weights






Protein-protein interaction data often contain a considerable amount of false positives
originating from experimental or curation errors (41, 72). In this Chapter, we propose
a novel method to assign confidence scores to interactions in a given network (91). Our
method exploits solely the structure of interaction networks to assess the confidence of
their individual interacitons and does not require additional information on the network
elements.
3.1 Introduction to protein-protein interaction confidence
assessment
Accurate physical interaction networks are fundamental to answering questions about
how the biochemical machinery of cells organizes matter, processes information, and
carries out transformations to perform specific functions leading to various phenotypes
(73, 151). Toward this goal, a number of experimental and computational techniques,
some of which were mentioned in Chapter 1, have been devised and applied to map
the interactions of human proteins (50, 79, 133, 152) and those of model organisms
such as yeast (61, 84, 103, 160, 167, 183). Despite their incompleteness (72, 171),
physical interaction networks already serve as a basis for numerous methods aiming to
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elucidate biological processes in health and disease (67, 80, 146). Current interactome
maps are contaminated with false positives that can make up a considerable portion
of the data (41, 43, 85, 114, 171). False positive interactions dim the explanatory light
of interaction networks and also decrease the predictive value of methods using such
data. Even more gravely impacted are integrated networks due to the much higher
probability of overlap for true interactions than false positives from different datasets,
which leads to an accumulation of false interactions in integrated data. It is thus of
primary importance to derive confidence values for individual interactions, which can
serve to refine current interactome maps or can be used as interaction weights.
Von Mering et al. (114) showed that interactions detected with multiple methods are
more likely to be true than those detected with a single method, which is why literature
evidence is an often used criterion for interaction confidence. Nevertheless, interactions
with weaker evidence (e.g. those detected with a single method) found in interaction
databases are not necessarily false: First, protein interaction detection techniques are
barely comparable, and interactions consistently measured with one technique could be
missed by another e.g. because the techniques tend to detect interactions with different
stability. For instance, affinity purification combined with mass spectrometry captures
interactions that are stable over time, while yeast-two-hybrid is able to detect more
transient interactions. Second, the coverage of existing interactome screens is still
limited (72), meaning that not all possible interactions have been tested even for well-
studied organisms, and different large-scale studies usually test different subsets of the
possible interactions. Third, a vast amount of the reported interactions are not even
captured by database curators (35). This is also evidenced by the fact that databases
mining interactions from the literature are mostly complementary (Table 2.2 in Chapter
2), suggesting that database curators tend to cover unique subsets of publications to
extract interactions from. As a consequence, filtering out interactions with a weaker
publication evidence is certainly sub-optimal as it would discard many true interactions
that have been tested rarely, seen rarely by database curators, or are specific to a certain
discovery technique.
Other strategies to validate protein-protein interaction data beside considering the
literature evidence of interactions involve comparison of the interactions with reference
datasets. For example, interactions between proteins that are often found together in
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known protein complexes are more likely to be true. However, knowledge about pro-
tein complexes is still limited. Similarly, interactions between proteins that are known
to participate in the same biological processes are more likely to be true, but unfor-
tunately, pathway annotation is still lacking for many proteins (146). Several further
approaches have been proposed for interaction confidence assessment, many of which
are reviewed in (157) and (31). Most of these methods are meta-approaches that require
the integration of additional data like interaction homology (43), co-expression of genes
encoding interacting proteins (43, 44, 97), or a combination of these and other evidence
features (12, 106, 145). While being certainly useful, such additional data are not al-
ways available, and may introduce additional bias and ambiguity since results depend
on the particular data employed. Other methods do not require additional features and
use network topology alone to predict interaction veracity (30, 66, 104, 135). Network
topology-based methods are the tools of choice for interaction confidence assessment if
other types of data are limited; moreover, topological features can be combined with
other features to achieve better predictions. Topology-based methods are motivated by
the fact that at various levels, the topology of interaction networks encodes biological
properties which are largely independent of the biochemical function of the individual
members of the network (5, 14, 18). Importantly, modularity of interaction networks is
currently the most successful concept for addressing the dynamics of cellular processes
(4, 54, 73).
Goldberg and Roth (66) proposed a network topology-based approach for interac-
tion confidence assessment where the number of common neighbors of a pair of predicted
interaction partners counts in support of the interaction. They defined interaction con-
fidence as the level of enrichment of common network neighbors of interacting proteins.
It is quantified by the hypergeometric distribution p-value given the number of common
neighbors and total network neighbors of both interacting proteins. The underlying
principle of the approach has been established in seminal studies demonstrating that
biological networks are marked with short interaction paths separating random pairs of
proteins in the network (small-world property), and densely connected local neighbor-
hoods (neighborhood cohesiveness property) (153, 175). False positive protein-protein
interactions are expected to violate the network cohesiveness property more frequently
than true interactions. Recently, Kuchaiev et al. (104) proposed a different method
that embeds interaction networks into a low-dimensional Euclidean space based on
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network metrics (shortest path length) and then calculates confidence of interactions
depending on the Euclidean distance between proteins within that space. The basis of
the approach is the geometric graph model that was proposed to better reflect biological
networks than e.g. the small-world model (74). Although its biological basis remains
elusive, the authors argue that applying the geometric graph model to assess network
distance should be consequently more reliable. Both of these topology-based meth-
ods assign confidence as numerical values to protein-protein interactions in a network
and are additionally able to predict new interaction candidates by assigning confidence
scores to non-interactions. However, both methods have certain shortcomings. The
method by Goldberg and Roth is able to assess the confidence of those interactions
whose participants have common neighbors only. Often, however, interacting proteins
do not share neighbors. The method of Kuchaiev et al. appears limited in that it re-
quires fixing six free parameters. For example, one of them is the prior probability for
interactions. To calculate it, knowledge about the sizes of the proteome and interac-
tome of the species under study is crucial. Unfortunately, even for well-stidied model
organisms such as yeast, these quantities can still only be guessed at (71, 72). The rest
of the parameters are algorithm-specific and barely have any biological motivation.
Here, we propose CAPPIC (cluster-based assessment of protein-protein interaction
confidence) – a novel network topology-based approach that exploits the inherent mod-
ular structure of interactomes for confidence assessment of individual protein-protein
interactions (91). Our method combines the basic principles of the topology-based
methods described above: high neighborhood interconnectedness of a couple of pro-
teins and short distance between them (the features exploited by Goldberg and Roth
and Kuchaiev et al., respectively) are indicators that both proteins participate in the
same module. We apply Markov clustering (45) to the line graph (176) of an interac-
tion network to dissect it into modules of interactions. As demonstrated in (123), this
strategy can generate interaction clusters that significantly overlap with known biolog-
ical pathways. Notably, the interaction clusters overlap in their protein constitution.
This is biologically more meaningful than clustering the proteins into disjoint modules
because pathways and protein machineries are known to overlap (61, 73). The rationale
behind our approach is that proteins that are specific to certain modules are expected
to have more interactions with proteins that are specific to the same modules than with
other proteins (54). Intuitively, we assign low confidence to interactions that disagree
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network property Tarassov-all Tarassov-hq Yu-Ito-Uetz Gavin-Krogan CPDB-yeast Costanzo
method PCA PCA Y2H AP-MS multiple genetic
node count 2238 (2293) 889 (1124) 1647 (2018) 2864 (2964) 6073 (6075) 4278 (4278)
link count 9360 (9646) 2407 (2770) 2518 (2930) 12006 (12068) 74332 (74333) 63927 (63927)
clustering coefficient 0.14 0.24 0.06 0.24 0.19 0.06
links in triangles 5861 (62%) 1761 (73%) 440 (17%) 8701 (72%) 63385 (85%) 47822 (74%)
mean shortest path length 3.7 5.6 5.6 4.3 2.7 2.9
links with ≥ 3 publications 546 (5%) 419 (17%) 782 (31%) 4090 (34%) 6324 (8%) 2546 (3%)∗
Table 3.1: Yeast interactome maps used in this study for method evaluation. Interac-
tion discovery methods: PCA: protein-fragment complementation; Y2H: yeast-two-hybrid;
AP-MS: affinity purification coupled to mass spectrometry. The node and link counts cor-
respond to the largest connected network component which is used for method evaluation;
the according numbers of items in the complete network are given in brackets. The number
of links in triangles corresponds to the number of interactions whose interaction partners
share at least one network neighbor. ∗In the case of the Costanzo network, the number in
the last row corresponds to the number of genetic interactions also reported in (36).
with the modular structure of biological networks and high confidence to those that
comply with it. While the aim of CAPPIC is to detect false positive interactions, an
approach based on the same idea of high link density within network modules has been
proposed for identifying false negative interactions (182).
We applied CAPPIC and the methods by Goldberg and Roth and Kuchaiev et al.
on a comprehensive benchmark of six interaction networks from yeast (Table 3.1) to
assess and compare their performance. The six datasets were: 1) a network published
by Tarassov et al. (160) that was generated using the protein-fragment complementa-
tion assay technology (Tarassov-all); 2) a sub-network of Tarassov-all obtained by the
authors after applying several filtering steps (160) (Tarassov-hq); 3) a combined net-
work of interactions found by yeast-two-hybrid screens (Yu-Ito-Uetz) comprising the
networks published by Yu et al. (183), Ito et al. (84) and Uetz et al. (167) (retrieved
from (183)); 4) a combined network of interactions detected by affinity purification cou-
pled to mass spectrometry (Gavin-Krogan) published by Gavin et al. (61) and Krogan
et al. (103) and downloaded from BioGRID (149); 5) a comprehensive physical inter-
action network from the interaction meta-database ConsensusPathDB, release 6(yeast)
(92) obtained by the integration of multiple publicly accessible interaction repositories
(CPDB-yeast); and 6) a genetic interaction map published by Costanzo et al. (38) ob-
tained at a stringent experimental cutoff (Costanzo). The physical interaction networks
constitute a representative benchmark since they result from different, most prevalent
methods: yeast-two-hybrid, protein-fragment complementation, affinity purification,
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and integration of interaction data from multiple methods. We applied our method
additionally to the genetic interaction map by Costanzo et al. to provide evidence that
it is not limited to physical interactome maps.
3.2 CAPPIC: A novel approach for interaction confidence
assessment
3.2.1 Assessing protein interaction confidence by random walk inter-
action clustering
As mentioned previously, binary physical interaction data are usually modeled as graphs
where nodes represent proteins or genes and edges represent interactions between them.
For assessing the confidence of every interaction in such a network, we apply the fol-
lowing strategy (illustrated in Figure 3.1). First, the interaction graph is transformed
into its line graph (176) where interactions are represented by nodes, and proteins are
represented by links that connect their interactions (step 1 in Figure 3.1). In other
words, while the original interaction graph is a network of proteins connected by their
interactions, its line graph is a network of interactions connected by their shared pro-
teins. Second, we employ Markov clustering – an algorithm for network clustering
through random walk simulation (45) – on the line graph to dissect it into disjoint
clusters of interactions (step 2 in Figure 3.1). In the third and last step of the approach
(step 3 in Figure 3.1), we evaluate the distribution of interactions among the resulting
clusters. It is a key point that interactions of a given protein can be clustered together,
or distributed among multiple clusters. A protein is specific to a cluster if the cluster
is enriched in interactions of that protein. We utilize the cumulative hypergeometric
distribution to assess the enrichment of links of a given protein in a given interaction
cluster. We define the fidelity Fp,c of a protein p to cluster c as the value of the cumu-
lative hypergeometric distribution function (Equation (3.1)) given Lp,c, the number of
interactions of protein p in cluster c; Lp,·, the total number of interactions of p (called
the degree of p); L·,c, the total number of interactions in c; and L·,·, the total number
of interactions in the network:











3.2 CAPPIC: A novel approach for interaction confidence assessment
Figure 3.1: Outline of our interaction confidence assessment method. In the
input interaction network (upper left picture), proteins are labeled with letters (A, B,
etc.) and interactions between them are represented by edges. In the first step of the
approach, we create the line graph of the given network where nodes represent interactions
(labeled A–C, A–D, etc.) and edges represent shared interaction participants. In the second
step, we use Markov clustering on this line graph to dissect it into interaction clusters.
The clustering granularity is optimized in a previous step of the algorithm. Importantly,
proteins can be part of more than one cluster. The relative number of interactions of a
protein in a cluster determines how specific a protein is to that cluster. In the third step,
we calculate confidence values for every interaction based on how specific both proteins
are to the according clusters. The thickness of interaction links in the lower left picture
corresponds to the calculated interaction confidence values for this example network.
The value of the fidelity Fp,c lies between 0 and 1, with values near or equal to 1 if
a protein p is specific to cluster c, i.e. if it has relatively many links in that cluster.
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For a fixed Lp,c it holds that the smaller the cluster (smaller L·,c), the greater the
fidelity value – meaning that big clusters are less informative. Finally, if all the links of
two proteins lie within a cluster, the fidelity is greater for the protein with the greater
degree.
We define interaction confidence as the product of the fidelity values of both inter-
acting proteins to the cluster c which the interaction has been assigned to:
confidence(lp1,p2) = Fp1,c · Fp2,c (3.2)
Interactions get high confidence values if both proteins are specific to the cluster con-
taining the interaction, and low confidence values when one or both of the proteins are
not specific to the cluster.
3.2.2 Optimal clustering granularity is reliably determined through
partial network rewiring
The interaction confidence scores calculated by CAPPIC are dependent on the granu-
larity of the interaction clustering. It has been shown that modules in many complex
networks, including protein interaction maps, are organized in a hierarchical manner
(127). Accordingly, interaction clustering can yield protein complexes, cellular ma-
chineries (like the spliceosome), pathways, or higher-order biological processes depend-
ing on the clustering granularity. To estimate the granularity for a given network that
will result in the best discrimination between true and false interactions, we first create
an instance of that network where a small part of the interactions are randomly rewired
to produce a set of false interactions. Our experiments have shown that rewiring 3%
of the links is a good choice because this yields a false interaction set of reasonable
size while keeping most of the network structure intact. In the rewiring procedure,
pairs of interactions are selected at random and two of the proteins are swapped (so
that no real interaction is reconstituted), thus generating two false interactions for two
real ones while preserving each protein’s degree. We additionally make sure that the
network stays connected as a single component. Then, we apply our confidence scoring
algorithm to this partially rewired network instance using different inflation values.
The inflation parameter of the Markov clustering algorithm essentially controls clus-
tering granularity (45). For every inflation value, we quantify the significance of the
difference between the confidence score distributions of the rewired and the remaining
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non-rewired links. This is done with the Wilcoxon rank-sum test under the alternative
hypothesis that the confidence scores of the non-rewired links are greater than the con-
fidence scores of the rewired links. The inflation value minimizing the Wilcoxon test
p-value is considered optimal.
The inflation scan is carried out in two steps: a coarse scan with step size of 0.1
within a fixed range I ∈ [1.1, 2.0] is followed by a fine scan with step size of 0.025
around the optimal inflation value ±0.1 resulting from the coarse scan. In general,
the inflation parameter takes values from the interval I ∈ (1.0, 30.0] with higher values
resulting in finer granularity. In all our experiments the Wilcoxon test p-value peaked
at values far below 2.0, motivating the choice of this value as an upper boundary of the
inflation scan.
Our experiments have shown that the estimated granularity value is robust to the
introduced random rewiring as long as it is of reasonable extent: If the set of false inter-
actions obtained through random rewiring is too small, the granularity estimation will
lack statistical power, while if too many interactions are rewired, the network’s origi-
nal modular structure will be difficult to capture by the Markov clustering algorithm
and the estimate may be biased. For all networks CAPPIC was applied on, random
rewiring of 1%, 3%, 5%, or 10% of the interactions yielded identical or very similar op-
timal granularity estimates (data not shown). As mentioned above, we chose to rewire
3% in the inflation estimation step to ensure statistical power of the estimation while
keeping most of the network intact.
The inflation estimation approach described above builds on the assumption that
the optimal granularity value inferred from a partially rewired network instance (where
both false positive and false negative rates are increased compared to the real network)
is transferable to the real network. We aimed to scrutinize this reasoning and verified for
all reference networks that 1) the estimated optimal granularity was rather independent
of the random choice of links for rewiring; and 2) that interaction clusters were similar
for the intact and the partially rewired networks clustered with the same inflation value.
To test the first hypothesis, we created 100 instances of each of the six reference
networks (Table 3.1) where 3% of the links were randomly selected and rewired, and
performed an inflation value search for each. For every instance and every inflation
value, we calculated the Wilcoxon rank-sum test p-value reflecting the significance of
the score difference between original and rewired interactions (optimality criterion).
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Figure 3.2: Estimating optimal granularity for clustering through partial ran-
dom rewiring of input networks. 100 instances of every reference network were created
where 3% of the links were randomly rewired. The negative common logarithm of the
Wilcoxon rank sum test p-value reflecting the confidence score difference between rewired
and non-rewired interactions (red curves, left-hand-side Y-axis) was calculated for each
inflation value (X-axis). Moreover, the number of resulting clusters (blue curves, right-
hand-side Y-axis) is plotted against varying inflation. Thick lines indicate the median
values. We note that in the case of the Yu-Ito-Uetz network, the achieved p-value in the
optimization step was one to two orders of magnitude higher than for the rest of the net-
works. Intuitively, the reliability of confidence scores calculated by our method can be
appraised from the best achieved Wilcoxon rank sum test p-value in the inflation opti-
mization step. If the overall performance of confidence scoring for a network is bad, then
the score difference between random and real interactions in the optimization phase is
less significant. However, these p-values are not suited for a strict comparison between
networks.
The negative logarithm of the Wilcoxon test p-value and the number of clusters are
plotted against varying inflation value in Figure 3.2. For all six networks, the 100
partially randomized instances were highly consistent regarding the estimated optimal
inflation value. Figure 3.2 also shows that the number of clusters generated for the
network instances did not vary much for any given inflation value within the inflation
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search range.
To test the second hypothesis, namely that clusters have similar interaction compo-
sition for the intact and the partially rewired networks, we first clustered these networks
with the same inflation value (resulting from granularity optimization). Based on the
100 partially rewired instances, we calculated an interaction co-clustering matrix ri,j
which contained the relative frequencies that two interactions, i and j, end up in the
same cluster for all partially rewired network instances where both interactions survive
rewiring. We compared this matrix with the binary co-clustering matrix ci,j reflect-
ing interaction co-clustering for the intact reference network. We defined a clustering
agreement score to measure the agreement between ri,j and ci,j :








By definition, the clustering agreement equals 1, if and only if pairs of interactions that
are co-clustered in the non-rewired case are also co-clustered in all rewired instances
where both interactions have survived rewiring. The agreement value is around 0 if
clusters in the non-rewired and rewired instances are completely independent from
each other, and equals -1 if they are negatively correlated. Figure 3.3 shows the two
co-clustering frequency matrices and their global mutual agreement for each reference
network. In all six cases we found the cluster composition of the real network in
high agreement with its partially randomized instances. We conclude that clusters
are very similar for the original and the partially rewired networks clustered with the
same inflation value. In other words, the link randomization we introduce to estimate
the optimal granularity in the clustering step of the algorithm does not change the
clustering result as such.
3.3 Comparative assessment of the performance of CAP-
PIC on yeast networks
3.3.1 True positive interactions are assigned higher confidence than
false positives
We measured the performance of CAPPIC and compared it to the previously proposed
network topology-based interaction confidence assessment methods ba Goldberg and
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Figure 3.3: Interaction co-clustering matrices. For each reference network and its
100 partially rewired instances, we calculated interaction co-clustering matrices ri,j and
ci,j for a fixed inflation corresponding to the estimated optimal value. This figure shows
the co-clustering heatmaps for the non-rewired networks (ci,j , below the diagonal) and the
rewired instances (ri,j , above the diagonal). Also provided is the overall agreement between
both co-clustering matrices which, by definition, equals 1 if and only if pairs of interactions
that are co-clustered in the non-rewired case are also co-clustered in all rewired instances
where both interactions have survived rewiring. The agreement is around 0 if clusters in
the non-rewired and rewired instances are completely independent from each other, and
equals -1 if they are negatively correlated. For the six reference networks, the agreement
ranges from 0.63 to 0.97.
Roth and Kuchaiev et al. using five yeast physical interaction networks and one yeast
genetic interactome map, covering major interaction inference methods (Table 3.1).
We first constructed positive (literature interactions) and negative (random links)
link sets and then evaluated the methods using receiver operating characteristic (ROC)
analysis. The positive set for each network consisted of interactions that are reported
at least three times in the literature (ranging from 3% to 34% for the six reference
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networks, Table 1), since such interactions have been shown to be on average more
reliable (114, 171). An exception was made for the Costanzo network because of the
scarcity of genetic interaction data: the positive set in this case consisted of interac-
tions that are also reported in (36). Literature evidences for all networks were retrieved
with the interaction evidence mining ConsensusPathDB plugin (122) described in the
previous Chapter. For each network, the negative interaction set for the ROC analysis
was constructed by randomly rewiring a small subset (3%) of the interactions. For the
partially rewired network networks we ranked interactions according to confidence as
calculated with CAPPIC or reference methods and created receiver operating charac-
teristic (ROC) curves.
The reference methods were applied as follows. We set the number of yeast genes
to 6,000 in the method by Goldberg and Roth, which we implemented in R (82).
The parameters of the method by Kuchaiev et al. (implementation downloaded from
http://www.kuchaev.com/Denoising) were set as follows: priorEdge=0.002945 (which
results when the estimated yeast interactome size of 53,000 interactions (72) is divided






priorEdge; dim=5 (default); d=3 (default); learnSetSize=min(5,000 or half the number
of interactions); delta=1.0; and stopEps=0.01 (default). In the case of the Costanzo
network, we set dim=3 because the program (run on a standard AMD X2 5600+
machine with 8GB of RAM running Matlab version 7.10.0.499 under Linux) did not
return results within five days for a higher number of dimensions.
ROC curves were created by successively comparing the interactions ordered by
confidence against the real positive (literature interactions) and real negative (random
links) sets to determine the true positive and false positive rates at each step. The true
positive rate is defined as the fraction of true positives from the real positives, while the
false positive rate is the fraction of false positives from the real negatives. The perfor-
mance of a given confidence assessment method in ranking positive interactions higher
than negative ones was quantified with the area under the ROC curve (AUC). The AUC
is around 0.5 if a method does not perform better than random interaction ranking,
and is closer to 1 the better it ranks positive interactions higher than negative ones.
Since the constitution of the negative and positive sets involves a random process (that
is, the random selection of interactions for rewiring), we repeated the procedure 100
times and averaged the ROC results. In general, CAPPIC assigned higher confidence
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Figure 3.4: ROC analysis measuring the performance of CAPPIC in compari-
son to the methods by Goldberg and Roth and Kuchaiev et al.. False positive rate
(1-specificity) is plotted against true positive rate (sensitivity) for each of the six reference
networks. Since the definition of a negative interaction set in the performance assessment
involves a random process, the ROC plots summarize the outcome of 100 runs. Plots show
the average ROC curves (thick lines), their standard error bands (dotted lines), as well as
the mean area under the ROC curve (AUC) of all runs. The ‘X’-marks on the green ROC
curves correspond to the fraction of true/false interactions whose proteins share network
neighbors and are thus scored by Goldberg and Roth’s method.
to true interactions than false interactions (Figure 3.4). The area under the ROC
curve (AUC), which quantifies the confidence ranking performance, was as high as 93%
for the Gavin-Krogan network. At a fixed specificity of 90% our method reached 86%
sensitivity, outperforming the other topology-based methods. None of the methods in
question showed convincing performance on the combined Y2H network Yu-Ito-Uetz.
In this example, Goldberg and Roth’s method successfully classified interactions whose
proteins shared network neighbors; however, such interactions comprised only 17% of
Yu-Ito-Uetz (see ‘X’-mark on the green line in Figure 3.4 and row “links in triangles” in
Table 1) while the rest of the interacting protein pairs did not share network neighbors.
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Nevertheless, Goldberg and Roth’s method outperformed CAPPIC by 6% AUC in the
case of the Costanzo genetic interaction network, whereas the method by Kuchaiev
et al. did not discriminate between true and false interactions better than random
(AUC=50%). Based on the results for all six networks, we conclude that the method of
Goldberg and Roth is suitable for identifying a relatively small set of high-confidence
interactions but often does not provide predictions for a considerable fraction of the
data. On the other hand, the method by Kuchaiev et al. and our approach generate
confidence scores for the complete dataset, and are therefore more appropriate when
the aim is to assess the confidence of all interactions or to filter out a relatively small
sub-set of low-confidence interactions. In all cases, CAPPIC outperformed the method
by Kuchaiev et al. in terms of AUC. It should be noted that in order to define a reli-
able negative link set, we destroyed some real interactions (increasing the false negative
rate) and simultaneously introduced the same number of false positive interactions into
the network, diminishing the biological signal in its structure. Thus, the AUC values
reported here probably underestimate the real performance.
3.3.2 Cluster-based confidence scores corroborate experimental inter-
action evidence
To compare confidence values calculated by CAPPIC with experiment-based interaction
scores, we exploited the fact that some of the interactions in Tarassov-all have been
designated high-quality by the authors based on experimental interaction intensity
(160). We checked whether our method assigned significantly higher confidence scores
to high-quality interactions than to the rest of the interactions in Tarassov-all. As
shown in Figure 3.5, the confidence score distributions of both interaction sub-sets were
different. Using the Wilcoxon rank-sum test we confirmed that confidence values were
greater for high-quality interactions than for the rest of the links in Tarassov-all (p-value
< 3 ∗ 10−10). The high agreement between cluster-based interaction confidence scores
and experimental interaction weight for the Tarassov-all network was corroborated by
a significant Spearman rank correlation between both (ρ = 0.3, p-value < 10−5).
53
3. CLUSTER-BASED ASSESSMENT OF PROTEIN-PROTEIN
INTERACTION CONFIDENCE
Figure 3.5: Histogram of confidence scores for interactions in Tarassov-all cal-
culated by our method. The normalized histograms of interaction confidence scores are
shown for the complete Tarassov-all network, as well as for its high-quality (Tarassov-hq)
and non-high-quality parts. WRST: Wilcoxon rank sum test of the difference between
confidence score distributions of both network parts. Note that the Y-axis is interrupted
to better show the differences between the three datasets.
3.3.3 High-confidence interactions are more consistent in biological
process and cellular compartment annotation
Interacting proteins are expected to participate in related biological processes and to
be co-localized in compartments of the cell (116). Therefore, Gene Ontology (GO)
(8) annotations of interacting proteins agree more often than expected by chance. We
utilized the semantic similarity of GO biological process and cellular compartment an-
notations of proteins predicted to interact as a performance measure of our approach.
If confidence values reflect the correctness of discovered interactions, we expect inter-
actions with higher confidence score to have a higher average semantic similarity of the
proteins’ GO annotations.
To test this, we calculated the GO semantic similarity (GOSemSim) values for all
interacting proteins in each network in respect to their biological process and cellular
component annotations. This was done using the method proposed by Resnik (129)
implemented in the software package GOSemSim version 1.8.0 (181). GO annotations
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Figure 3.6: Correlation of CAPPIC interaction confidence with semantic simi-
larity of Gene Ontology co-annotations. Interactions from every network are ranked
by confidence and divided into five equal sized bins (X-axis); for each bin, the average
semantic similarity of GO biological process (blue) and cellular component (green) anno-
tations of interacting proteins is shown (Y-axis). Additionally, the pale continuous lines
correspond to the mean GO semantic similarity over the complete network rather than the
separate bins. The dashed lines reflect the average GO semantic similarity of random pairs
of proteins from the network.
inferred from physical interaction (GO evidence code ‘IPI’) were excluded from the
semantic similarity calculation to avoid circularity. For each network, interactions
were ordered by increasing confidence score and divided into five equal sized bins.
The average semantic similarity values for interacting proteins within each bin were
calculated (Figure 3.6). Additionally, the mean GO semantic similarity for random
pairs of proteins from the according network was assessed by completely rewiring the
networks while preserving each protein’s degree and then calculating the mean GO
semantic similarity of links in those randomized networks (Figure 3.6, dashed lines).
The GOSemSim generally correlated with interaction confidence. In several extreme
cases (e.g. Gavin-Krogan), the average GOSemSim of low-confidence interactions was
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barely distinguishable from the average GOSemSim of random protein pairs (dashed
horizontal lines), while the higher-confidence interactions reached average GOSemSim
far above the average value of all interactions in the according network (continuous
horizontal lines). These results suggest that there are more false links among the
lower-confidence interactions than among the higher-confidence ones.
Following this line of thought, we asked whether removing low-confidence interac-
tions from clusters generated in our confidence assessment procedure would improve the
consistency in pathway annotation of proteins remaining in the clusters. Pereira-Leal
et al. have shown that Markov clustering applied to the line graph of a comprehen-
sive interactome map yields clusters that are significantly consistent with KEGG (94)
biological pathways (123). In the context of our method, low-confidence interactions
are those involving proteins that are not specific to the according cluster, thus likely
do not belong to its pathway context. We successively removed interactions ranked by
confidence from clusters generated in the Markov clustering phase of our confidence
assignment procedure. At each step, the resulting reduced interaction clusters were
transformed into non-weighted lists of genes or proteins involved in interactions re-
maining in the cluster as in (123). We quantified the consistency of the gene or protein











In this measure based on Shannon’s entropy (144), C is the number of interaction
clusters, pj,s is the relative frequency of pathway s in cluster j, and n is the number of
KEGG pathways. In general, the consistency value increases, the more homogeneous
the clusters are regarding pathway classification of the contained proteins or genes. We
found that the pathway annotation consistency of interaction clusters increased with the
number of low-confidence interactions removed (Figure 3.7, continuous lines). Results
were clearly different when the order of the removed interactions was reversed, i.e.
when high-confidence interactions were removed first (dotted lines in Figure 3.7). This
confirmed that lower-confidence protein-protein interactions do not fit in the pathway
context of the according clusters as well as higher-confidence ones. Unlike the five
physical interaction networks, in the case of the Costanzo genetic interaction map the
consistency increased faster when interactions were removed from clusters starting with
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Figure 3.7: Interaction cluster refinement. Each reference network was transformed
into its line graph and clustered with the estimated optimal inflation value for that network.
Interactions were ranked according to confidence and successively removed from the ac-
cording clusters. Pathway annotation consistency (Y-axis) was plotted against the number
of interactions removed from interaction clusters (X-axis) starting with the low-confidence
(continuous line) or high-confidence (dotted line) interactions.
the high-confidence interactions. The reason for this is probably rooted in the fact
that most of the detected genetic interactions involve proteins in different pathways
(between-pathway interactions) than proteins in the same pathway (within-pathway
interactions) (70). Overall, the results suggest that our approach can be used to obtain
more refined functional modules in physical interaction datasets.
3.3.4 Construction of a high-quality yeast physical interactome
We used CAPPIC confidence scores of interactions in the most comprehensive avail-
able yeast physical interaction network, CPDB-yeast, to derive a high-quality yeast
physical interactome. The distribution of confidence scores for this network is shown
in Figure 3.8 A). Evident from the results presented in the previous sections is that
low-confidence interactions probably represent false positives, which was also confirmed
by the small fraction of lower-confidence interactions reported more than twice in the
literature (Figure 3.8 B). Based on the distributions of confidence scores and literature
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Figure 3.8: Confidence scores and literature evidence for the CPDB-yeast net-
work. A Histogram of of CAPPIC confidence scores of the interactions in CPDB-yeast.
Approximately 33% of the scores are very small (near 0.0), and roughly 35% are big (near
1.0). B Interactions of the CPDB-yeast network were ordered by CAPPIC confidence score
and divided into ten bins of equal size. For each bin (x-axis), the fraction of the interactions
reported in more than two publications is indicated (y-axis).
evidence (Figure 3.8 A and B), we selected the top 35% interactions with the highest
confidence scores, as well as interactions found in more than two publications from the
remaining 65%, to construct a high-quality yeast physical interactome. The resulting
network contained 28,241 interactions between 3,779 proteins. Similar to CPDB-yeast,
the high-quality interactome consisted of one large connected component and only 14
interactions were isolated. On the other hand, the high-quality interactome had a much
higher average clustering coefficient than CPDB-yeast (0.33 for the high-quality inter-
actome as opposed to 0.19 for CPDB-yeast), indicating a more pronounced modularity
(175). Moreover, it possessed a longer average shortest path (4.1 for the high-quality
interactome versus 2.7 for CPDB-yeast).
The high-quality interactome is available for download from the ConsensusPathDB-
yeast web page (http://cpdb.molgen.mpg.de/YCPDB) beside the complete physical
interactome. It should be noted that, apart from this filtered dataset, we did not use
CAPPIC to discard any interactions integrated in ConsensusPathDB.
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Figure 3.9: CAPPIC as a web tool at http://cpdb.molgen.mpg.de/cappic.
3.3.5 CAPPIC as a web tool for interaction confidence assessment
To provide easy and fast access to CAPPIC, we have implemented it as a web tool
available at http://cpdb.molgen.mpg.de/cappic (Figure 3.9). Optional parameters en-
able influencing how the optimal granularity for the given network is estimated. The
source code is also available from the web site.
3.4 Discussion
Network topology-based approaches are motivated by the fact that the structure of
interaction networks is not random but reflects biological functionality (14). Modularity
is a topological property that is inherent to protein-protein interaction networks (54,
61, 127). It is often exploited by graph clustering-based approaches aiming to find
network modules reflecting pathways or protein complexes (10, 123). We propose a
novel method (CAPPIC) to assess the confidence of individual protein interactions in
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an interaction network. Our method exploits solely network modularity for estimating
the confidence of interactions and does not require any additional knowledge about the
interacting proteins. We demonstrate the power of CAPPIC in discriminating between
true and false interactions on the basis of five physical protein interaction networks and
one genetic interaction map.
CAPPIC outperforms previous topology-based approaches by Goldberg and Roth
and Kuchaiev et al. in assigning continuous confidence scores to all interactions in a
given physical interaction network. The method of Goldberg and Roth is dependent on
shared network neighbors of interacting proteins; however, many interacting proteins
do not share neighbors. Absence of shared network neighbors is especially prevalent for
interactions in binary networks constructed using a bait-prey strategy, where links exist
between baits and preys only. As a result, the method of Goldberg and Roth scores
many interactions (83% of the interactions in the Yu-Ito-Uetz network, for example)
with a confidence value of zero. This is a particularly strong drawback of that method,
considering that many approaches operating on networks take as input probabilistic
rather than binary data. Thus, the ultimate goal of confidence assessment is often
to score all interactions in the network rather than disregard a large portion of them.
In particular, all proteins with a single available interaction would be disregarded by
Goldberg and Roth’s method (as such proteins do not share neighbors with their in-
teraction partner), albeit these single protein associations could give important clues
about the function of these proteins. On the other hand, the method by Kuchaiev et al.
is able to assign continuous scores to all interactions in a given network. Nevertheless,
their method requires fixing six free parameters. These include e.g. the dimension of
the Euclidean space for embedding, the prior probability for an interaction (which can
currently only be guessed at because the interactome size of no species is known (72)),
and several algorithm-specific parameters. In contrast, our method does not require
any parameters or reference interaction sets. The only parameter that influences the
resulting confidence scores – clustering granularity – is optimized internally for each
individual input network. Our results have shown that the number of clusters obtained
at the optimal granularity tends to be small for all reference networks, ranging from
10 to 60 clusters (see Figure 3.2). This condemned our initial concerns that interac-
tions executing essential crosstalks between related pathways could be assigned low
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confidence. Because the optimal granularity tends to be very coarse, closely related
pathways will probably not be separated but clustered together.
CAPPIC should be applicable to any binary network (of biological or non-biological
nature) with an inherent modular structure. CAPPIC fails to generate reliable confi-
dence scores in cases where modularity is not pronounced, i.e. if many of the real links
within modules are missing. This is probably the case with the Yu-Ito-Uetz reference
network: here, the topological signal that our method exploits seems to be weaker,
therefore it achieves only 58% AUC on average. Absence of modularity in this exam-
ple is evidenced by the relatively low clustering coefficient (175) of 0.06 which is four
times lower than that of the Gavin-Krogan network where CAPPIC achieves 93% AUC.
Moreover, the Yu-Ito-Uetz dataset is the sparsest of all reference networks (Table 1).
For the ConsensusPathDB-yeast network, which includes the rest of the reference net-
works used in this Chapter along with interactions from many further large-scale and
small-scale experiments, our method performs well (AUC = 81%).
Due to the multiplicative nature of the interaction confidence definition, the method
should be extendable (with an appropriate cardinality normalization) also to complex
interaction data (i.e. non-binary interaction data). Furthermore, other mathematical
functions instead of the cumulative hypergeometric distribution function can be applied
for assessing the fidelity value of a protein to a cluster (which is used to derive inter-
action confidence). For example, in our initial experiments we defined fidelity as the
number of interactions of the protein found in the cluster normalized either by the total
number of interactions of the protein (that is, its degree), or by the maximum number
of its interactions found together in any cluster. Also, we experimented with using as
fidelity value the negative logarithm of the hypergeometric test p-value reflecting the
enrichment of interactions of a protein in the cluster (that is, fidelity was defined in
this experiment as − log(1− Fp,c) where Fp,c corresponds to Equation (3.1)). None of
these alternative fidelity definitions yielded better results in the method’s performance
assessment as per Section 3.3.1.
Unlike the reference methods by Goldberg and Roth and Kuchaiev et al., CAPPIC
is able to accommodate experimental evidence weights of interactions. Interaction
detection techniques often associate such weights with predicted interactions, reflecting
for example the number of times an interaction is observed in repetitions of a yeast-two-
hybrid experiment (171, 183) or the reporter intensity value in the case of a protein-
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fragment complementation assay (160). If available, such weights can be exploited by
our method in its random walk-based interaction clustering step. This can improve the
interaction clustering result and consequently increase the performance of confidence
assessment. Moreover, the ability to incorporate experimental interaction weights helps
to avoid interaction data pre-filtering, commonly executed to derive binary interaction
networks (where pairs of proteins either interact or not). Such filtering of probabilistic
interaction data is inherently associated with data loss. However, since we set out
to estimate the performance of CAPPIC in comparison to other methods that cannot
accommodate interaction weights, we did not make use of this advantage in this work
and considered all interactions equal.
Although our approach alone is able to successfully rank true and false interactions
and achieves up to 93% AUC on the reference interactomes, it can be combined with
other lines of interaction evidence like protein co-expression and interaction homol-
ogy (157). Aggregation of different features holds the promise of even more reliable





networks and expression data
Gene expression profiling is a powerful technique for measuring the activity of thousands
of genes simultaneously, often applied to distinguish phenotype-specific gene signatures,
i.e. lists of genes with a consistent activity change in a certain phenotype (for example
a disease) compared to a control. A major concern, however, is that differentially
expressed genes found in different studies analyzing the same phenotypic condition
are barely overlapping (47). This is mainly attributed to the inherent variability of
biological systems and of techniques for measuring gene expression. Significantly higher
coherence between different studies is often found at the level of biochemical pathways
where the distinguished genes function (33, 40, 80, 155). This finding has shifted
analyses of expression data to a more pathway-centric perspective. This perspective
can give more concrete hypotheses about the molecular mechanisms underlying the
phenotype under study than simple lists of differentially expressed genes. The analysis
of expression data at the level of interactions and pathways has proven useful for various
purposes (discussed below). At this, integration of interactions and pathways is a
crucial prior step, because it increases the coverage of the real interactome and thus
enables more accurate predictions of methods based on these data. In this Chapter,
we show the utility of the integrated and de-noised human interaction network from
ConsensusPathDB in the context of expression data. We describe a simple approach to
63
4. ELUCIDATING DISEASE MECHANISMS WITH INTEGRATED
INTERACTION NETWORKS AND EXPRESSION DATA
identify phenotype-associated network hot-spots and causative genes. The approach is
implemented as part of the expression data analysis module of the ConsensusPathDB
web interface at http://cpdb.molgen.mpg.de. Furthermore, we present a method for the
integrated analysis of large-scale transcriptomics/proteomics and metabolomics data at
the level of known pathways (23), and introduce the first available computational tool
for this purpose, accessible at http://impala.molgen.mpg.de (90).
4.1 Introduction: the benefits from integrating interac-
tion and expression data
In the previous chapters, we emphasized that the high degree of organization of matter,
information flow and energy transformations in the cell is reflected in the structure of
interaction networks (14). Building on this, many approaches have been developed to
extract network structures with specific topological properties from large-scale interac-
tion data. For example, different methods exist for the detection of network modules:
densely connected sub-networks which can be assigned a distinct biological function
(73) from protein-protein interaction data (19, 141). In parallel, functional groups of
genes are often searched in whole-genome gene expression data. This is routinely done
by searching for genes with similar activation patterns with clustering techniques, with
the presumption that co-regulated genes are often involved in the same biological pro-
cesses (48). Motivated by the correlation between interaction and co-expression data
(62), computational methods have been developed that integrate both data types (some
are mentioned below). While both interaction and expression data are often incomplete
and may contain large numbers of false positives, their integration should be beneficial
because signals supported by both are more likely to be of biological relevance than
those supported by either data type alone (62).
The integration of interaction and expression data has a successful history in a
variety of contexts. One class of methods search for modules of genes corresponding to
biochemical pathways or complexes supported by physical interaction and co-expression
evidence simultaneously (69, 81, 143, 150, 168). Furthermore, the existence of disease-
specific functional modules (65, 118) has motivated a group of related methods aimed
at mining such disease-relevant modules directly from large-scale interaction data in
conjunction with phenotype-associated gene expression data (32, 166, 169). Identified
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modules have potential applications in molecular medicine as they have been shown
to possess biomarker potential (32, 80, 162). Unlike the conventional, one-dimensional
approach of selecting differentially expressed genes as disease biomarkers, network-
based biomarkers constitute groups of interacting genes whose joint expression signature
is discriminative for disease. Network-based biomarkers can achieve better classification
accuracy and reproducibility across datasets than lists of discriminative genes (32). A
further advantage over gene lists is that the identified networks can provide concrete
hypotheses about the molecular mechanisms of disease in terms of interactions with
altered activity (49).
While the methods cited above attempt to construct de novo disease modules from
a whole-genome interaction network given expression data, a complementary strategy
is to assess a priori defined functional gene sets to spot the ones showing an abnormal
activity in a phenotype under study (40). Functional gene sets often correspond to the
genes found in manually curated pathways, retrieved from pathway databases or the
Gene Ontology (GO) (8). The key assumption here is that if a known pathway contains
significantly many differentially expressed genes, or if the pathway genes show a jointly
significant differential expression, then the pathway is dysregulated in the phenotype.
Such pathways may be indicative or even causative of the phenotype, and have also been
shown to possess biomarker potential (17, 165). Among the most popular approaches
to identify phenotype-associated pathways are over-representation analysis (described
in detail below) and gene set enrichment analysis (155).
A further research area where the integration of interaction and expression data has
proven useful is the identification of genes causative of complex diseases (55, 96, 113,
158, 173). The main assumption behind such methods, and the basis for our integrative
approach described in the next section, is that complex diseases like cancer are often
caused by mutations in one or a few genes and the biological signal initiated by these
mutations is propagated from the causative genes through their interactions to provoke
differential expression of downstream genes. While the differentially expressed genes
are often secondary manifestations of disease rather than its cause and thus can vary
strongly from patient to patient, they are expected to lie near the mutated genes in
a network of interactions (32, 34, 60, 65, 118). Following this assumption, existing
methods (e.g.(96, 158)) for the identification of causative genes usually attempt to find
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small sets of genes that lie near the differentially expressed ones in a physical interaction
network.
4.2 Network-based functional gene sets in aid of causative
gene identification
As mentioned above, manually curated pathways from public pathway databases and
ontologies are routinely used in pathway-based analyses of expression data aiming to
highlight biological processes associated with a phenotype of interest. Unfortunately,
currently available curated pathways face several problems: First, functional annota-
tion is still lacking for nearly half of the human genes (146)(Figure 4.1 A). Second, the
composition of a biochemical pathway is a matter of subjective judgment as pathway
boundaries are generally unclear (169). Even pathways of the same name found in dif-
ferent databases rarely agree regarding their composition (see Figure 2.4 in Chapter 2).
Third, there is a widely recognized research bias toward inferring pathways associated
with certain diseases like cancer; thus, currently defined pathways are predominantly
disease-related. For example, several databases like NetPath and InnateDB are focused
only on disease-related signaling (Chapter 2). This research bias naturally causes that
disease pathways preferentially appear in the results of pathway-driven gene expres-
sion data analyses, challenging reliability of the latter. Fourth, pathway databases
typically contain process-specific pathways but often miss essential pathway crosstalks
which are important for pathway coordination, and whose dysregulation may play an
equally important role in disease onset and progression like the pathways themselves.
For example, dysregulation of the crosstalk between Wnt and Notch signaling has been
implicated in cancer (37).
The availability of genome-wide interaction networks enables the definition of func-
tional gene sets based on network neighborhood. In principle, these functional sets
overcome all hurdles of manually curated pathway definitions listed above. Network-
based sets are motivated by the fact that interacting genes are likely to have similar
functions, shown for instance in the case of physical interaction networks in (116, 146).
For example, Sharan et al. demonstrated the correlation of interaction network dis-
tance (defined as shortest path length) with functional distance (defined as semantic
similarity of Gene Ontology annotations) of proteins, pointing out in particular that the
66
4.2 Network-based functional gene sets in aid of causative gene
identification
Figure 4.1: Pathway annotation of human genes and its relation with protein
interactions. A Pie diagram showing the number of human genes with and without
biological pathway annotation according to the Gene Ontology (GO). B Correlation of
functional distance (quantified with GO semantic similarity) with interaction network dis-
tance for human proteins. Reproduced from (146).
direct neighbors of a protein in a physical interaction network often share its functions
(146) (Figure 4.1 B).
We constructed network neighborhood-based functional gene sets from the inte-
grated network content of ConsensusPathDB (Chapter 2), which was de-noised before-
hand on the basis of cluster-based protein-protein interaction confidence (Chapter 3).
These gene sets can be used in enrichment and over-representation analyses to high-
light network hot-spots with an abnormal activity in a phenotype under study. The
identified sub-networks can yield hypotheses about the mechanisms behind the phe-
notype in terms of disrupted interactions. Importantly, each neighborhood-based set
per definition has a distinguished central gene (detailed below) and the central gene
of a sub-network that is dysregulated in a phenotype is a more probable cause for the
dysregulation. The reasoning behind this assumption is that a gene that is mutated
does not necessarily show a change in expression, but its mutations often disturb its in-
teractions with other genes and hence affect the expression of the interaction partners
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(32, 34, 65, 118). Below, we detail the construction of network neighborhood-based
gene sets from ConsensusPathDB’s integrated content, and overview statistical meth-
ods that can be used to identify those which are dysregulated in a phenotype. Based
on two example cases, we demonstrate that while being relatively simple, our approach
is able to pinpoint known causative genes from cancer patient data.
4.2.1 Functional gene sets based on integrated network neighborhood
(NESTs)
As the basis for construction of functional sets we used the integrated interaction data
assembled in ConsensusPathDB from dozens of public interaction databases. Notably,
the interaction network contains multiple types of interactions (gene regulations, sig-
naling, catalysis, and physical interactions) of human genes/proteins. Prior to defining
functional sets, we de-noised the binary physical protein-protein interaction content
in ConsensusPathDB based on cluster-based interaction confidence and literature ev-
idence as per Chapter 3. This was important because spurious interactions resulting
from protein-protein interaction screens in principle accumulate in the meta-database
and might diminish the predictive power of our approach. In contrast, the gene regu-
latory interactions and biochemical reactions currently contained in ConsensusPathDB
have been primarily mined from the literature by experts, thus these data are expected
to contain much less spurious interactions and do not necessitate filtering. The physical
interaction content was de-noised by excluding 10% of the interactions with the lowest
CAPPIC confidence and a single publication evidence. The procedure was analogous
to Section 3.3.4 in Chapter 3; however, the confidence score and literature evidence
thresholds were relaxed here as we aimed to retain all proteins in the network (whereas
in Section 3.3.4, more than 1/3 of the proteins were removed at the chosen thresholds).
For every gene in the database we define a neighborhood-based entity set (NEST)
including the gene itself and its network neighbors (Figure 4.2). More precisely, each
NEST contains a gene as a center, as well as genes encoding proteins that interact
physically with the products of the center, genes regulating or being regulated by the
central gene transcriptionally, genes whose products participate in the same biochem-
ical reaction as the products of the central gene, and genes encoding enzymes that
catalyze or modulate successive biochemical reactions (in case that the central gene
itself encodes an enzyme or a modulator). Two biochemical reactions are successive
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Figure 4.2: Construction of neighborhood-based entity sets (NESTs). Each
NEST contains a central gene and all of its gene neighbors in the integrated interaction
network. This example network comprises the interactions (circular nodes) of a gene A:
one complex protein interaction (PPI1), two gene regulatory interactions (GR1, GR2), and
three biochemical reactions (BR1: complex binding reaction, BR2 and BR3: metabolic
reactions involving the metabolites M1, M2 and M3, catalyzed by A and G, respectively).
Network neighborhood of genes is defined as either direct physical interaction of gene
products, direct gene regulation (where the central gene is either the regulator or is being
regulated), co-participation in a biochemical reaction, or catalysis of successive metabolic
reactions (i.e. reactions sharing a non-hub metabolite).
if a product of one reaction is a substrate for the other (in Figure 4.2, BR2 and BR3
are successive reactions sharing the metabolite M2). Because many reactions are con-
nected through non-specific metabolite hubs (for instance, ATP), we have constrained
the definition of successive reactions to reactions sharing metabolites participating in
five or less reactions from the whole network in total. NESTs with different centers and
identical gene composition are collapsed together, resulting in NESTs with more than
one center. Based on the content of ConsensusPathDB (release 19), we have created
19,666 distinct NESTs with these definitions. The number of genes per NEST, being
87 on average (Figure 4.3 A shows the NEST size distribution), is comparable to the
size of manually curated pathways. However, the vast majority of NESTs are not
subsumed by such pathways: the fraction of pathway-annotated NEST members found
within the same manually defined pathway is 0.46 on average (Figure 4.3 B shows the
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Figure 4.3: Characteristics of neighborhood-based entity sets. A Histogram of
NEST size (number of genes per NEST); B Overlap between the gene compositions of
NESTs and pathways; C Histogram of the number of different databases contributing
interactions per NESTs; D Number of different types of interactions per NEST.
according distribution). For each NEST, this fraction was calculated as the size of the
largest overlap with any pathway divided by the number of NEST members. This result
means that many of the NESTs may represent pathway crosstalks. Most notably, in
contrast to manually curated pathways, NESTs comprise the vast majority of human
genes. Furthermore, a view on the number of sources per NEST reveals that in the
majority of cases, more than one database contributes interactions for NEST composi-
tion (4.3 source databases per NEST on average, see Figure 4.3 C for the distribution).
For instance, NESTs centered by SMAD4 or by members of the histone deacetylase
family are composed with interaction data from as many as 20 source databases. Many
NESTs are constructed from physical interactions only (Figure 4.3 D) because the
currently available interaction knowledge is dominated by such interactions. This is
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mainly due to the high throughput of protein interaction discovery techniques. 30% of
the NESTs are contributed by both protein interaction and biochemical reaction data,
while 5% include in addition gene regulatory relations, limited by the small number
of gene regulatory interactions (2,270 interactions) compared to protein interactions
(138,470 binary or complex interactions) in ConsensusPathDB.
4.2.2 Statistical approaches for identifying dysregulated NESTs
Given an expression dataset obtained e.g. by microarray-based or RNAseq-based profil-
ing (139, 174) of a phenotype under study compared to a control, NESTs can be tested
for differential activity using statistical methods. Entity set over-representation
analysis is a classical approach used in gene set-based analysis to assess the significance
of overlap between a predefined functional set, e.g. a NEST, and a custom list of genes
that usually comprises the ones that show significant differential expression in the phe-
notype of interest (40). To quantify the significance of overlap, the hypergeometric test
(identical to the one-tailed version of Fisher’s exact test) is commonly used. Suppose
that a NEST consists of n genes, the input set comprises m differentially expressed
genes, and the background has N genes (Figure 4.4 A). The background typically com-
prises all genes whose expression has been measured and which are found in at least
one NEST. The probability that exactly k entities from the input set are found by
chance in the NEST is given by the probability mass function of the hypergeometric
distribution:











For an observed overlap of size K between a NEST and an input gene list, we rather
aim to assess the probability that an overlap of this size or larger is obtained by chance.
This probability corresponds to the hypergeometric test p-value for the observation K:













The p-value is small for big overlap sizes K that are unlikely to appear by chance,
supporting the alternative hypothesis that the overlap is caused by a biological effect.
NESTs containing significantly many differentially expressed genes correspond to hot-
spots in the interaction network with altered activity between phenotypes.
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Figure 4.4: Over-representation and enrichment analyses. A and B: squares rep-
resent genes, the big ovals represent the gene background and the small ovals represent
a functional gene set, e.g. a NEST. A For over-representation analysis, a relatively small
set of genes (shown in black) is first to be distinguished from the expression data often.
Conventionally, this set comprises the differentially expressed genes. Over-representation
analysis then quantifies for each NEST whether it contains significantly many of these dis-
tinguished genes. B in contrast, enrichment analysis takes as input the complete measured
set of genes rather than just the differentially expressed ones. Here, continuous values
must be provided for every measured gene reflecting its expression level in the case and
control phenotypes. The color of the squares in B scales with the change in expression
of genes between the phenotypes (red: over-expression in the case compared to control;
green: underexpression in the case compared to control; yellow: no expression change).
Over-representation analysis faces several practical problems associated with how
the input set of genes is distinguished from the expression data. First, the list of differ-
entially expressed genes is ambigouous and depends on the applied statistical test and
the chosen significance level. Second, in order to assess the significance of differential
expression with enough statistical power, repeated measurements per phenotype are
necessary. Third, genes that pass the significance threshold are considered equally im-
portant for the phenotype under study, regarless of the magnitude of their expression
change. The reason is that the hypergeometric test is a discrete test that cannot han-
dle gene weights or ranks. These problems are overcome by entity set enrichment
analysis. A key point here is that no decision is made a priori regarding which genes
are differentially expressed and belong in the input set. Instead, enrichment analysis
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takes as input all genes that have been measured in the case and control phenotypes
with numerical values reflecting each gene’s expression in both phenotypes. Different
approaches can be applied to assess the enrichment of a functional set with up- or
down-regulated genes, probably the most established one being gene set enrichment
analysis (GSEA) (155). We utilize the paired Wilcoxon signed-rank test to assess the
significance of joint differential expression of genes contained in a functional category
such as a NEST. This test has been argued to be more suitable for enrichment analyses
than e.g. Student’s t-test, because its validity does not depend on a specific assumption
about the distribution of expression values (e.g. Gaussian) (110). Accordingly, the
Wilcoxon signed-rank test is more robust, in particular with respect to experimental
outliers often found in biological measurements. Suppose that a NEST has n genes, for
each of which a pair of expression values is provided. The NEST is thus represented
as a set of pairs (x1, y1), ..., (xn, yn), where xk is the expression value for the k’th gene
in the control phenotype and yk is its expression value in the case phenotype. First, a
vector z of expression differences is calculated such that zk = yk − xk. Observations
with no expression difference between the phenotypes, i.e. zk = 0, are excluded so z
has a possibly reduced size (denoted nr) compared to the number of genes n in the
NEST (nr ≤ n). The null hypothesis of the Wilcoxon signed-rank test is that the ex-
pression differences in the vector z are symmetric around a median of 0. To test it, the
absolute values |z1|, ..., |znr | are first sorted in ascending order and are assigned ranks
such that the smallest absolute value in z gets the smallest rank Ri = 1. A mean rank
is assigned to tied expression differences, i.e. where |zi| = |zj | 6= 0. The ranks of all
|zk| where zk > 0 are summed up to give R+. Similarly, R− is the sum of ranks of the
values |zk| where zk < 0. If the null hypothesis is true, then the values R+ and R− are
expected to be similar. The Wilcoxon signed-rank test statistic is S = min(R+, R−)
and its critical value for rejecting the null hypothesis depends on the sample size nr
and the chosen confidence level. Exact p-values can be obtained from tables for small
sample sizes nr, while for bigger nr, a normal approximation can be used because the
test statistic S tends toward the Gaussian distribution. If the genes with the biggest
expression difference in a NEST are overexpressed in the phenotype under study com-
pared to the control, then R− is very small (it equals zero if all genes in the NEST
are over-expressed), and the NEST is likely to be phenotype-associated. Notably, even
if no genes with individually significant differential expression are found in the NEST,
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the joint expression of the group of genes within the NEST may be significantly in-
creased or decreased. Thus, NEST enrichment analysis is able to identify interaction
sub-network that are dysregulated on a low but nonetheless consistent gene level in the
phenotype of interest.
It should be noted that Wilcoxon enrichment analysis is sensitive to pre-processing
of the input expression data. For example, if the measured expression of all genes in one
of the phenotypes is systematically higher or lower than in the other phenotype (e.g.
due to experimental error), then many NESTs will be spuriously highlighted. To avoid
this, expression values should be appropriately normalized such that that the expected
gene expression differences between phenotypes is zero. The input expression values
should also be logarithmized, in which case the Wilcoxon enrichment test deals with
gene expression fold changes rather than absolute expression differences in assessing
NEST de-regulation. This is generally advantageous because the dynamic range of
expression activity varies strongly across the genome (63), thus absolute expression
differences are barely comparable from gene to gene. As an example, transcription
factors are usually found at very low concentrations in the cell and even subtle changes
in their abundance often have a strong impact on the biology of the cell.
Because in over-representation and enrichment analyses many NESTs are typically
tested for a given input, it is crucial to control for multiple comparisons in order to avoid
a high false positive rate. Throughout our analyses we thus used the false discovery rate
(FDR) method, defined as the expected proportion of falsely rejected null hypotheses
(15). The FDR analogue of the p-value is commonly termed q-value.
4.2.3 Application 1: Network-based meta-analysis of prostate cancer
pinpoints known causative genes
We carried out a comprehensive meta-analysis of prostate cancer patient data involving
over-representation analysis of NESTs in order to unveil cancer causative genes.
Input dataset
To obtain an input list of genes that are commonly deregulated on the expression level
in metastatic prostate cancer, we combined results from 9 studies (Table 4.1) providing
a total of 11 datasets where samples from metastatic prostate cancer patients have
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been compared against primary prostate carcinoma through microarray-based whole-
genome expression profiling. All study results were retrieved from Oncomine 3.0 (130)
Study PubMed ID
Dhanasekaran et al. (2005) FASEB J. 19:243-5 15548588
Dhanasekaran et al. (2001) Nature 412:822-6 11518967
Holzbeierlein et al. (2004) Am J Pathol. 164:217-27 14695335
Lapointe et al. (2004) Proc Natl Acad Sci USA. 101:811-6 14711987
LaTulippe et al. (2002) Cancer Res. 62:4499-506 12154061
Tomlins et al. (2007) Nat Genet. 39:41-51 17173048
Vanaja et al. (2003) Cancer Res. 63:3877-82 12873976
Varambally et al. (2005) Cancer Cell. 8:393-406 16286247
Yu et al. (2004) J Clin Oncol. 22:2790-9 15254046
Table 4.1: Studies comparing whole-genome expression profiles of metastatic
prostate cancer against primary prostate carcinoma. The studies by Tomlins et
al. and Varambally et al. provide two different datasets each; the rest provide one dataset
each.
where a p-value reflecting the significance of differential expression is provided for each
measured gene in each study. From 19,500 genes measured in at least one dataset,
11,350 (58%) showed differential expression at a q-value threshold of 0.05 in one or
more of the datasets. Not a single gene was found to be differentially expressed in all 11
datasets, and only five genes (CTGF, CYR61, MGP, PDLIM5, and PPP1R12B) showed
differential expression in nine or ten of them (Figure 4.5). This result demonstrates
the high variability of differentially expressed genes across different studies, which often
hampers objective conclusions about the set of genes associated with cancer based on
their expression value.
For NEST over-representation analysis, we used genes that were found to be differ-
entially expressed at a confidence level q < 0.05 in more than half of the datasets in the
analysis (i.e. at least 6 datasets). The input gene list consisted of 191 genes, termed
DE genes (Table 4.2).
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Figure 4.5: Agreement of different studies focused on the same phenotypes
in respect of differentially expressed genes. The number of differentially expressed
genes found in at least n of the 11 datasets from Table 4.1 is plotted against the number
of datasets n.
NEST over-representation analysis results and discussion
With the DE gene list, NEST over-representation analysis highlighted 36 NESTs at an
FDR level q < 0.05 (the NESTs are listed in Appendix Figure A.2). They yielded a
total of 88 NEST center genes (termed NC genes, Table 4.3), because some of them
were centered by gene families or had multiple centers as per construction (see Section
4.2.1). For example, one of the NESTs was centered by the group “cytokine receptor”
comprising 39 genes, more than half of which were interleukin receptor genes 1.
We compared both the DE and the NC gene lists against the Cancer Gene Census
(58). The Census catalogs 457 genes for which somatic or germline mutations have
been causally implicated in cancer. We found that 11 out of the 191 DE genes (6%)
1The activity of the NEST centered by the “cytokine receptor” gene group points to inflammation,
which is likely a secondary manifestation of cancer rather than a cause.
76
4.2 Network-based functional gene sets in aid of causative gene
identification
ABI1 ACOX1 ACTA2 ACTG2 ADAM10 ALCAM ALDH1A2 AMOTL2 ASCL1
ATF3 ATP6V0C ATXN3 BMPR1A BTAF1 BTG2 CALD1 CALU CCBL2
CCL2 CCNB1 CCND2 CCNF CDC6 CDH11 CDK6 CHD2 CNN1
CNOT2 COX7A1 CSRP1 CTGF CTNND1 CTSO CYR61 DDIT4 DDR2
DIO2 DLG7 DST DSTN DUSP1 DUSP5 ECM2 EDNRA EGR1
EGR2 EVI5 FAM189A2 FBLN1 FHL1 FILIP1L FNDC3A FOXK2 FUCA1
GABRE GBP2 GLUD1 GOLGB1 GPD1L GULP1 H2AFV HEXB HLA-DQA1
HLA-DQB1 IDE IDS IER2 IFNAR1 IL6ST JUNB KCNMB1 KIAA0101
KIFC1 KLF4 KLF9 LEPR LGALS3 LMOD1 LRRFIP1 MCL1 MCM4
MED26 MEIS2 MFAP4 MGP MITF MMP7 MYH11 MYL9 MYLK
N4BP1 NAV1 NCKIPSD NEAT1 NFE2L2 NR4A1 NR4A3 NT5C2 NTRK2
OSBPL8 PAGE4 PAM PARM1 PBX1 PCP4 PCTK1 PDE4D PDE5A
PDE8B PDLIM3 PDLIM5 PELO PGM3 PKN2 PLAGL1 PLEKHC1 PLN
PPAP2B PPP1R12B PPP2R1B PRDX3 PRKACB PRPF40A PRPF4B PSMA7 PTN
PTPRK PTTG1 PYROXD1 RAB27B RAB4A RAD23B RAP1A RBM25 RBM3
RBM9 RBPMS RCAN2 RNF141 RPS23 RPS6KB1 SELE SFRS11 SFRS2B
SLAIN2 SLC22A3 SLC26A2 SLC2A10 SLC30A9 SLMAP SNAP23 SOAT1 SON
SORBS1 SORBS2 SORL1 SPARCL1 SPG20 SPOP SRD5A1 SRI SSPN
ST13 STAT1 STC2 SYNPO2 TAGLN TCEAL1 TCF7L2 TFRC TK1
TNFSF10 TNPO1 TOP2A TPM1 TPM2 TPX2 TSPYL1 UBE2C UBE2J1
UBE2S USP7 VCL VPS39 YY1 ZFP36 ZFX ZMYM4 ZMYND11
ZMYND8 ZNF354A
Table 4.2: DE (differentially expressed) genes. The 191 genes listed here were found
to be differentially expressed at a q-value threshold 0.05 in more than half of the prostate
cancer studies (see Figure 4.5). The genes that have been causally implicated in cancer (as
of the Cancer Gene Census, (58)) are underlined.
ACP5 ACTN4 ATF2 BMP2 BMPR1A CCNF CDC26 CDKN1A CDKN2A
CNTFR CSF2RA CSF2RB CSF3R CTNNB1 CXCR1 CXCR2 EPHB2 EPOR
GHR HCRT HLA-DQA1 HLA-DQB1 HOXA9 HOXB8 IFNAR1 IFNAR2 IFNGR1
IFNGR2 IL10R IL10RB IL12RB IL12RB2 IL13BP IL13RA1 IL15RA IL17RA
IL18R1 IL1R1 IL1RAP IL1RB IL2RA IL2RB IL2RG IL3RA IL4R
IL5RA IL6R IL6ST IL7R IL9R ITGA1 ITGB5 JAK1 JAK2
JAK3 JUN LEPR LIFR LMOD1 MAPK1 MAPK3 MGP MPL
MYH11 MYL12B MYL6B MYL9 OSMR PCNA PRKG1 PRLR PXN
SORBS1 SORBS3 STAT1 STAT2 STAT3 STAT4 STAT5A STAT5B STAT6
TLN1 TNFRSF10C TP53 TPM3 TPM4 TYK2 VCL
Table 4.3: NC (nest center) genes. These genes were found as centers of the 36 NESTs
(Appendix Figure A.2), each of which contained significantly many of the DE genes from
Table 4.2. The genes that have been causally implicated in cancer (as of the Cancer Gene
Census, (58)) are underlined. For example TP53, whose mutations are known to cause
cancer, was not contained in the differentially expressed gene list but was highlighted by
NEST over-representation analysis because many of its network neighbors are differentially
expressed. The interleukin receptor genes in the table (IL10R through IL9R) originate from
the center of a single NEST: “cytokine receptors” gene group (see main text).
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Figure 4.6: Overlap between differentially expressed (DE) genes, nest center
(NC) genes, and the Cancer Gene Census. Cancer causative genes cataloged by the
Cancer Gene Census are more over-represented in the NC set (p-value = 1.9e-9) than in
the DE set (p-value = 5.5e-3).
and 15 out of the 88 NC genes (17%) are believed to contribute to cancer onset when
mutated (Figure 4.6). The according genes are underlined in Tables 4.2 and 4.3. This
means that in this example, genes connecting many differentially expressed counter-
parts by various interactions are roughly three times more probable to be causative of
disease than the differentially expressed genes themselves. Only three disease causative
genes are shared by the DE and the NC list, demonstrating the ability of NEST-based
expression data analysis for finding new potential disease causes on top of the ones
spotted through gene expression profiling. Notably, the protein p53 (TP53) whose mu-
tations are known to cause cancer (75) was not found to be differentially expressed in
any of the nine studies considered here, but it was identified as the center of a NEST in
which differentially expressed genes were significantly over-represented. The 36 NESTs
formed a connected network, supporting previous findings that disease-associated genes
induce functional network modules (65).
A possible concern could be that because of the widely recognized research bias
toward elucidating interactions of disease genes (80), NESTs centered by such genes
would be preferentially highlighted. To address this potential issue, we assessed the
expected number of known causative genes among NEST centers in a null model. We
created 1,000 lists of randomly chosen genes of the same size as the DE list, and car-
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ried out NEST over-representation analysis with each random list. Instead of selecting
NESTs passing a fixed q-value threshold as in the analysis above (for almost all ran-
dom lists, no NESTs passed the q < 0.05 threshold), for every random input list we
selected the top 36 NESTs with the smallest q-value, and assessed the overlap of their
centers with the Cancer Gene Census. The expected overlap between NC genes and
the Cancer Gene Census estimated through this null model was 1.8 ± 1.6 (mean ±
standard deviation) genes, resulting in a Z -score of 8.0 for the observed real overlap
of 15 genes. The Z -score was defined as Z = (K − µ)/σ where K was the observed
overlap, and µ and σ were the mean and standard deviation estimated from the null
model, accordingly. In fact, the mean number of known causative genes in the NC lists
in the null model µ was similar to the random expectation for the number of known
cancer causative genes in the real NC list of 88 genes. Considering that the Census
comprises 457 genes and there are 22,902 different entities found as NEST centers, 88
of which were highlighted in our analysis, the random expectation for the number of
known cancer causative genes in the real NC list is ((457/22902) ∗ 88 = 1.8). These
results show that there is no recognizable effect of research bias on our NEST-based
approach.
4.2.4 Application 2: NEST enrichment analysis with numerical data
unveils cancer-related genes and highlights the hallmarks of can-
cer
As pointed out above, gene expression data can not always be summarized as lists of
differentially expressed genes, for example because statistically sound conclusions about
differential expression require several repeated measurements per phenotype. Often, the
data consist solely of numerical values corresponding to gene expression measurements
in a phenotype of interest and a in control phenotype. Here, we demonstrate the utility
of the Wilcoxon enrichment analysis method in this common scenario.
Input dataset
Gene expression data were obtained from the study of Yu et al. (184) where the
genome-wide gene expression of prostate carcinoma patients and metastatic prostate
cancer patients has been measured with Affymetrix chips. The data were retrieved from
Oncomine 3.0 (130), summarized in the form of normalized average gene expression
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values for both patient cohorts. We additionally filtered the data to exclude expressed
sequence tags (EST) that were not mapped to genes, as well as ambiguously identified
genes. This resulted in a list of 7807 genes, for each of which the mean expression
values for both patient cohorts were available.
NEST and pathway Wilcoxon enrichment analysis results and discussion
We tested for enrichment all NESTs from ConsensusPathDB release 16. Wilcoxon
enrichment analysis yielded 57 significantly enriched NESTs at an FDR threshold of
q < 0.1 (Appendix Table A.1). The most significantly enriched NEST (Wilcoxon
signed-rank test p-value=8.34e-6; q-value=0.0483) had Histone H3-K9 methyltrans-
ferase 2 (gene symbol: SUV39H2) as the NEST center. It has been constructed from
physical interaction and biochemical reaction information originating from overall nine
different source databases. The central gene, SUV39H2, plays a role in cell cycle,
transcriptional regulation and cell differentiation (Gene Ontology annotation, UniProt
keywords) and its mutations have been shown to increase the risk of cancer in human
and in mouse models (124, 180). It is important to mention that SUV39H2 itself has
not been measured in the microarray experiment, and thus was not contained in the
expression data set that we used for Wilcoxon enrichment analysis. However, many of
the genes within its interaction neighborhood showed jointly significant transcriptional
upregulation in metastatic prostate cancer compared to primary carcinoma. Figure
4.7 depicts the NEST as visualized by the ConsensusPathDB visualization framework,
where the Yu et al. data were overlaid on protein nodes as logarithmized gene expres-
sion fold change.
Further significantly enriched neighborhood-based entity sets were centered by ribo-
somal proteins (e.g., RS4Y2 HUMAN, RS21 HUMAN, RL40 HUMAN, RL34 HUMAN)
(in accordance with (170)), cell cycle proteins (e.g., CDK-activating kinase assembly
factor MAT1: MAT1 HUMAN, Cyclin-H: CCNH HUMAN, and MAP kinase p38 delta:
MK13 HUMAN), and the transcription factor SP1 (SP1 HUMAN) which has been sug-
gested to play a role in prostate cancer (185) (Appendix Table A.1).
We additionally tested for enrichment all manually created pathways from Con-
sensusPathDB (release 16), originating from overall nine pathway source databases.
The pathways that were significantly enriched at a q-value threshold of 0.1 are pro-
vided in Appendix Table A.2. The results clearly corresponded to the hallmarks of
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Figure 4.7: Neighborhood-based entity set (NEST) centered around SUV39H2
with gene/protein nodes colored according to expression fold change.. This inter-
action sub-network constitutes the NEST centered by SUV39H2 (Histone H3-K9 methyl-
transferase 2, highlighted with red frame in the network) and contains its direct physical
interactors, as well as enzymes of successive biochemical reactions. The network consists of
13 physical interactions (orange circles) and five biochemical reactions (green circles) from
nine different databases (interaction sources are encoded as edge colors). Gene expression
data from (184) are overlaid as log2(fold change) values on the physical entity nodes (rect-
angles). Protein products of measured genes are colored according to the fold expression
change (see legend), non-measured physical entities in the network are gray (note that the
NEST center itself has not been measured).
human cancer (68) as they pointed to dysregulation of the cell cycle, transcription,
translation, signaling, angiogenesis and immune response. For example, among the
manually curated pathways whose activity is significantly changed in metastatic cancer
compared to primary carcinoma were the “Ribosome pathway” (KEGG) (in agreement
with (170)); “Translation” (Reactome); “Mitotic cell cycle” (Reactome); “Interleukin-5
immune pathway (IL5)” (NetPath); “VEGF, hypoxia and angiogenesis” (BioCarta); as
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well as several cancer-related signaling pathways like “Signaling by GPCR” (Reactome);
“PDGFR-beta signaling” (Pathway Interaction Database); “Signaling to ERKs” (Re-
actome); “Signaling to RAS” (Reactome); “JAK/STAT signaling” (INOH). Notably,
KEGG’s “Non-small cell lung cancer pathway” was also among the most enriched path-
ways.
4.3 Extending the pathway analysis paradigm: joint path-
way analysis with transcriptomics and metabolomics
data
Pathway analysis aiming to find biological processes whose executive genes are dis-
turbed on the transcriptional level in certain phenotypes is an established technique
despite the problems mentioned above. Importantly, gene expression is not the only as-
pect of the cell that may be altered as an effect of disease. Disease often impacts other
vital processes as well, including the cell’s metabolism. For instance, a classic hallmark
of cancer cell metabolism is the Warburg effect (typical for proliferating cells): an in-
crease in glucose uptake and glycolysis to lactate even under normal oxygen conditions.
Furthermore, tumor cells are often found to exhibit higher rates of glutaminolysis,
fatty acid and lipid metabolism, and nucleotide synthesis (23, 77). Motivated by the
detectable impact of disease on metabolism, large-scale metabolomic techniques are in-
creasingly applied to measure the whole metabolite repertoire of cells (76) to ultimately
highlight metabolite biomarkers discriminative of disease (111, 172). Computational
methods and tools for pathway-driven interpretation of large-scale metabolomic pro-
files (27, 178) are emerging in parallel to analogous utilities based on whole-genome
expression profiles (78, 89, 156).
Since the cell is a complex system where gene expression and metabolism are highly
coordinated not only within but also between each other, analyzing just one of these
functional levels at a time is certainly sub-optimal for understanding the system’s nor-
mal or abnormal functioning. With the increasing parallel generation of gene expression
and metabolomics data for the same phenotypes, new methods and tools are urgently
needed to allow integrated analysis of such data.
In a proof-of-principle study, we demonstrated that combining transcriptomic and
metabolomic evidence for pathway association with a certain phenotype can aid path-
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way biomarker discovery (23). Briefly, on the basis of a panel of 59 cell lines obtained
from different types of cancer (140) we studied the associations between measured
genes and metabolites and the resistance of the cells to platinum-based chemoterapeu-
tics. The cell lines under study have been treated with four such chemoterapeutics
that were carboplatin-, cisplatin-, iproplatin-, or tetraplatin-based. Our goal was to
identify pathways relevant to general platinum sensitivity, as opposed to particular
platinum compounds. Figure 4.8 shows a schematic outline of the study approach.
As a first step, we derived a set of genes and a set of metabolites whose measured
expression / concentration values were significantly correlated with sentisivity to car-
boplatin, cisplatin, iproplatin, or tetraplatin. For each of the four drugs, we carried
out pathway over-representation analyses with the associated genes and metabolites
separately. The pathways, originating from many public pathway databases, were re-
trieved from ConsensusPathDB. Based on the pathway over-representation analyses
with genes, we identified four pathways that were coincidently over-represented at the
chosen significance level for all four drugs, and thus were likely relevant to general
platinum sensitivity (Figure 4.9 A). These pathways were “Rho GTPase cycle” (Reac-
tome), “T cell receptor pathway” (NetPath), “Apoptotic dna-fragmentation and tissue
homeostasis” (BioCarta), and “Integrin cell surface interactions” (Reactome). No path-
ways were coincident for all four drugs when over-representation analysis was performed
with metabolites (Figure 4.9 B). Next, we integrated both lines (transcriptomic and
metabolomic) of pathway-phenotype association evidence to identify further platinum
resistance-related pathways. Essentially, we assumed that pathways highlighted when
using transcriptomics or metabolomics data were independent because these data have
been obtained with independent techniques. Thus, to integrate both data types at the
pathway level we computed for each pathway a joint p-value pi,J = pi,Gpi,M where pi,G
and pi,M denote the over-representation p-values of the i
th pathway with respect to
genes and metabolites correlated with drug chemosensitivity, respectively. The added
value of the joint analysis compared to the separate gene-based and metabolite analyses
was assessed through two null models, the first assuming that genes and metabolites
identified as significantly associated to a phenotype were randomly selected, and the
second null model assuming that pathways were selected randomly (see (23) for details).
The combination of evidence for pathway association with drug resistance enabled the
identification of six pathways generally related with resistance to platinum (Figure
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Figure 4.8: Pathway-level integration of transcript and metabolite data: a
schematic overview of the study design. Large-scale gene expression, metabolomic,
and drug sensitivity data obtained from the NCI60 tumor cell line panel (140) were used
to distinguish genes and metabolites associated with chemosensitivity to four platinum-
based cancer drugs (carboplatin, cisplatin, iproplatin or tetraplatin). For each of the four
drugs, the lists of distinguished genes and metabolites were used separately and jointly for
pathway over-representation analyses aiming to identify pathways associated with common
chemosensitivity to platinum. Reproduced from (23).
4.9 C). For the two new candidate pathways emerging from the joint pathway analy-
sis, “Triacylglyceride biosynthesis” (Reactome) and “Base excision repair” (Reactome),
phenotype association evidence on either the transcriptomic or the metabolomic level
was not significant enough; however, the two lines of evidence were agreeing and the
joint p-value was significant. Details on this study can be found in (23).
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Figure 4.9: Pathways associated with platinum resistance based on transcrip-
tomic, metabolomic, and combined evidence for phenotype association. Each
Venn diagram shows the numbers of pathways related to the four drugs based on the tran-
scriptomics data (A), metabolomics data (B), or joint metabolomics and transcriptomics
data (C). Reproduced from (23).
To enable the scientific community to easily integrate transcriptomics/proteomics
and metabolomics data at the pathway level, we developed a web tool called IM-
PaLA: integrated molecular pathway-level analysis (90) (http://impala.molgen.mpg.de;
Figure 4.10). IMPaLA performs pathway over-representation analyses with lists of
genes/proteins and metabolites (e.g. genes with differential expression and metabolites
with significant concentration change in a certain phenotype), or Wilcoxon pathway
enrichment analyses with numerical transcriptomics/proteomics and metabolite con-
centration data. As a source for predefined pathways, IMPaLA currently uses 11
freely available databases contributing over 3,000 manually curated pathways, most
of which comprise both genes and metabolites. As in our proof-of-principle study,
evidence of pathway association to the phenotype under study derived on the gene
expression and metabolite concentration levels is combined, allowing for the identifica-
tion of phenotype-associated pathways that would not be highlighted when analysis is
applied to any of the separate functional levels alone.
4.4 Discussion
The identification of causative genes and pathways governing disease onset and pro-
gression is one of the major problems in contemporary molecular biology. Toward this
goal, different approaches have been devised that make use of genome-wide interaction
85
4. ELUCIDATING DISEASE MECHANISMS WITH INTEGRATED
INTERACTION NETWORKS AND EXPRESSION DATA
Figure 4.10: IMPaLA: a web tool for integrated pathway-level analysis of tran-
scriptomics and metabolomics data. A IMPaLA input screen including the logos of
the 11 pathway source databases. B Output screen with a ranked list of pathways showing
i.a.: i : a link to each pathway in the according source database; ii : the size of each path-
way in terms of entities also present in the background list, followed by the number of all
pathway entities as in the source database; iii the p- and q-values from the joint analysis
with genes and metabolites.
networks or curated pathways integrated with large-scale transcriptomics, proteomics,
or metabolomics data.
We devised a simple approach to put forward the added value of prior integra-
tion and confidence-based filtering of interactions, tackled in the previous Chapters,
for interpreting gene expression data. Our approach aims to identify interaction net-
work hot-spots with altered activity and candidate causative genes in respect of a
phenotype for which gene expression data are provided. Notably, it combines the ba-
sic principles of both mainstream complementary strategies for disease-related pathway
identification: Similar to methods for de novo identification of context-specific modules
(32, 166, 169), the functional modules are mined from interaction networks. However,
the sub-networks are defined a priori and, given expression data, each sub-network
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is assessed through over-representation or enrichment analysis as in classical pathway
analyses (40, 155). Furthermore, the sub-networks comprise both large-scale protein in-
teractions and manually inferred interactions from signaling, regulatory, and metabolic
pathways. Thus, our approach closes the gap between the two mainstream strategies
for interaction- and pathway-based interpretation of gene expression data. It yielded
promising results when applied to prostate cancer patient data as it highlighted genes
with known causal role in cancer, even if they were not represented in the expression
data. The combination of interaction integration, de-noising, and using network neigh-
borhood information in conjunction with gene expression data appears to be key for
the identification of disease genes.
Notably, our network-based method considers only the direct interaction neigh-
borhood of every gene separately rather than attempting to explain the entire set of
observed expression effects at once with a minimal set of few causative genes like some
of the previous methods (e.g. (96)). A local search for dysregulated regions in the net-
work is motivated by the fact that disease often impacts the whole cell and is therefore
reflected not only in the expression of downstream counterparts of causative genes.
Rather, many effects observed at the gene expression level are not directly associated
with the causative genes. In cancer, for example, the reproductive machinery of the
cell is highly active due to the proliferative nature of the disease. In this light, the
reported increase of ribosome production in cancer cells (170), while certainly being a
hallmark of cancer, is more likely its secondary effect than its primary cause.
In a parallel line of work within the context of omics data interpretation we ex-
tended the pathway analysis paradigm to integrate transcriptomics/proteomics with
metabolomics measurements of a given phenotype on the level of biochemical pathways.
In a recent publication (23) summarized above we showed that combining evidence of
pathway disregulation on both gene expression and metabolite concentration levels al-
lows for the identification of phenotype-associated pathways that would be missed when
pathway analysis is applied to any of these functional levels alone. We developed the
first available computational tool for such integrative analyses (90).
A natural further development of the two contributions presented in this Chapter,
namely 1) the definition of functional gene sets (NESTs) from a network comprising
physical, regulatory, signaling and metabolic reactions in aid of disease gene identi-
fication from expression data, and 2) the integration of omics data at the pathway
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level, would be to combine both concepts. Since the interaction network in Consensus-
PathDB involves more than 5,000 metabolites additionally to human genes/proteins,
sub-networks can be constructed such that they include metabolites. When both gene
expression and metabolite measurements are present for a phenotypic condition, their





System biology aims to provide a mechanistic view on cellular processes in health
and disease. Toward this aim, knowledge of all biomolecular interactions in the cell
is crucial. Large interaction datasets for several species are already available, albeit
they likely represent only parts of the underlying real interactomes. A system-level
picture of cellular biology is still limited also by the quality of the available data and
by the way available data are handled. In this thesis, we addressed the problems
that protein-protein interactome maps often contain many false positives, and that
interaction data often reside in complementary, heterogeneous databases. Furthermore,
we tackled the problem that gene signatures for complex diseases are often inconsistent
from experiment to experiment, and are barely sufficient for explaining the causes and
mechanisms of those diseases without taking into account interaction knowledge.
First, we developed a meta-database called ConsensusPathDB (89, 92) to solve the
recognized problem that existing interaction knowledge is scattered across many public
repositories that are complementary and barely compatible regarding their data model
and format. ConsensusPathDB integrates several different types of interactions, in-
cluding gene regulatory, signaling, metabolic, and protein-protein interactions, as well
as manually defined pathways from a total of 26 databases. With several examples we
demonstrated the necessity of interaction data integration. For instance, many of the
interactions of any particular gene would often be missed if a single primary database
is used, as we showed for the well-studied p53 protein. This could have grave impact on
many areas of biological research, for instance in drug development where predictions
about the drug impact are based on knowledge of the target’s interactions. Similarly,
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pathway databases contain complementary sets of manually defined pathways, and
even homonymous pathways from different sources show grave differences in their com-
position. Pathway-based analyses of gene expression data, however, require unbiased
pathway data to ensure accurate hypotheses. Moreover, we showed that results of topo-
logical analyses of interaction networks could be different according to which databases
the networks are retrieved from. Our interaction integration efforts have resulted in a
human interactome map of unprecedented coverage, and have enabled a more complete
view on cell biology at the molecular level. This interactome can be used in various
contexts through a public interface (http://cpdb.molgen.mpg.de) offering a rich palette
of functionalities for interaction query and visualization, interaction network validation
and extension, and most notably, for network- and pathway-based analysis of tran-
scriptomics/proteomics data. Moreover, a database interface plugin for Cytoscape was
created to automate the process of evidence mining and novelty assessment for protein-
protein interactions (122). We initially developed the plugin to assess the sensitivity of
a mammalian-two-hybrid interaction screen (126). ConsensusPathDB is rebuilt auto-
matically every three months with the newest versions of the source databases to ensure
that its content stays up-to-date, and new interaction resources are added at the rate
of approximately one resource per release (Appendix Figure A.1). There are further
interaction types like genetic interactions that are currently missing in the database
but will be added in the future.
The second problem tackled in this thesis is the high rate of false positives of-
ten found in protein-protein interaction data, arising from experimental or literature
mining errors. We developed a novel approach called CAPPIC (cluster-based assess-
ment of protein-protein interaction confidence) (91) that exploits solely the topology
of a protein interaction network to assess the confidence of its individual interactions.
CAPPIC requires no parameters or reference sets for confidence scoring and optimizes
algorithmic parameters intrinsically. On the basis of several different yeast protein-
protein interaction datasets, we showed with ROC analysis that our approach achieves
a better performance than previous network topology-based methods in assigning con-
fidence to all interactions. Confidence scores calculated by CAPPIC are affirmed by a
positive correlation with Gene Ontology co-annotation of interacting proteins, and also
correlate with experimental interaction evidence. We have implemented CAPPIC as
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a publicly accessible web-based tool at http://cpdb.molgen.mpg.de/cappic, where the
source code is also available for free download.
The third research area approached in this thesis is the elucidation of molecu-
lar causes and mechanisms of complex diseases such as cancer using interaction and
pathway knowledge in conjunction with gene expression data. Toward this goal, many
methods have been developed that integrate interaction or pathway data with transcrip-
tomics or proteomics data to yield hypotheses about genes, interaction sub-networks, or
known biological processes related with disease. Such approaches require comprehen-
sive and error-free models of the cell’s molecular circuitry to ensure accuracy of results.
By combining interaction integration with de-noising based on interaction confidence
scoring, we have created a more complete and more accurate human interactome to
answer this need. We devised a simple strategy that exploits this interactome to iden-
tify centric, neighborhood-based interaction sub-networks (called NESTs) with altered
activity in gene expression profiles. Our approach is similar to classical pathway anal-
yses in that predefined gene sets are tested for over-representation or enrichment with
disease-relevant genes; however, the underlying sets are defined from a genome-wide
network integrating different interaction types and do not result from manual cura-
tion. Although NESTs are certainly not as likely to contain exclusively genes with
the same or similar functions as manually curated pathways, they have several advan-
tages over such pathways e.g. when it comes to genome coverage and bias. Notably,
identified NESTs can be suggestive for causative genes associated with the phenotype
under study. This was demonstrated with two example cases based on expression data
from prostate cancer patients, where many genes were recovered whose mutations are
known to cause cancer. Our approach was implemented within the gene expression data
analysis module of the ConsensusPathDB web interface at http://cpdb.molgen.mpg.de.
Within the context of disease mechanism elucidation, we outlined a second integra-
tive approach called IMPaLA that combines transcriptomics/proteomics with metabolo-
mics data on the level of predefined pathways (23). It can be applied when both gene
expression levels and metabolite concentrations have been measured in a phenotype
under study and the goal is to select pathways whose association with the phenotype
is supported by either or both of these datasets. IMPaLA was implemented as a web
server available freely at http://impala.molgen.mpg.de (90). To our knowledge, this is
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the first tool for the joint analysis of gene expression and metabolite data on the level
of pathways.
Currently, gene expression, gene regulation, protein binding, protein modifications,
metabolic reactions, metabolite dynamics, and other important cellular processes are
still mostly studied in isolation as if they were not deeply interlinked and dependent on
each other in the cell. Nevertheless, a tendency toward large-scale integration of these
and other aspects is clearly recognizable in contemporary research as an important step
toward better understanding of the molecular mechanisms governing life.
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Figure A.1: Growth of ConsensusPathDB’s unique interaction content since
its initial publication. ConsensusPathDB is rebuilt automatically every three months
with the newest versions of its source databases, and new databases are integrated at the
rate of approximately one database per release. The plot shows the number of unique
interactions in ConsensusPathDB for each release since its initial publication (89); newly
integrated databases are listed for each release.
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Figure A.2: NESTs where cancer metastasis-associated genes are significantly
over-represented. 36 NESTs where genes differentially expressed in metastatic prostate
cancer (DE genes) are significantly over-represented are listed. For each NEST, the name
of the central physical entity, the NEST radius (1 means that all entities in the NEST
are direct neighbors of the center), the NEST size (number of physical entities in the
NEST, followed by a corrected size according to the background), the number of DE genes
contained, the p- and q-values of the hypergeometric test, as well as the source databases
that contribute interactions to the NEST (see ConsensusPathDB web page for color key)
are listed. Note that the majority of NESTs comprise data from several resources.
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Enriched interaction neighborhood based sets
set centers set size measured genes p-value q-value set sources
Histone H3-K9 methyltransferase 2 43 24 8.34e-06 0.0483 11
Trap gamma 143 87 1.2e-05 0.0483 8
Myosin regulatory light polypeptide 9 34 30 1.82e-05 0.0483 6
PPA1 106 86 2.49e-05 0.0483 6
5S rRNA; 5.8S rRNA; 28S rRNA 120 80 2.62e-05 0.0483 1
np1l4 human 96 79 3.03e-05 0.0483 5
Hsc70 137 108 4.42e-05 0.0521 8
SET domain containing (lysine methyltrans-
ferase) 7 (EC:2.1.1.43)
40 20 4.77e-05 0.0521 9
40S ribosomal protein S4, Y isoform 2 81 59 5.13e-05 0.0521 1
PP2A-regulatory subunit B delta-2 isoform 217 143 5.45e-05 0.0521 13
peroxiredoxin 6 (EC:1.11.1.7 1.11.1.15) 211 145 6.5e-05 0.0531 6
Fructose-bisphosphate aldolase A 311 236 6.91e-05 0.0531 13
MAT1 229 146 8.17e-05 0.0531 11
MAP kinase p38 delta 115 95 8.21e-05 0.0531 11
lactate dehydrogenase B 174 130 8.85e-05 0.0531 9
Splicing factor 3B subunit 1 86 67 0.000101 0.0531 1
CHAF1A 59 47 0.000102 0.0531 10
SRP Receptor subunit alpha 110 74 0.000107 0.0531 7
SP1 290 210 0.00011 0.0531 13
eRF3 96 67 0.000115 0.0531 6
G-protein gamma 9 (GBGT2) subunit 364 202 0.000117 0.0531 7
Trap beta; SEC61 gamma 114 75 0.000122 0.0531 4
NudC 222 154 0.000138 0.0572 9
SET domain containing 1A (EC:2.1.1.43) 63 38 0.000145 0.0577 9
HSP90B1 263 195 0.000179 0.0639 8
T-cell receptor alpha chain 90 32 0.000195 0.0639 4
T-cell receptor alpha chain V region CTL-
L17 precursor
91 32 0.000195 0.0639 2
SEC11C; SPCS1; SPCS3 105 70 0.000198 0.0639 1
7SL RNA (ENST00000410687); 7SL RNA
(ENST00000410707)
110 74 0.000201 0.0639 1
hKNL1/CASC5 135 74 0.000206 0.0639 8
MARCKS 99 81 0.000207 0.0639 8
Nup85 458 137 0.000214 0.0639 9
nasp human 124 102 0.000234 0.0679 7
SPCS2 110 72 0.000245 0.0689 7
Protein disulfide isomerase P5 190 145 0.000285 0.0759 6
HDAC1 495 351 0.000291 0.0759 18
Centromere protein P 122 65 0.000309 0.0759 2
Centromere protein N 123 65 0.000309 0.0759 3
Centromere protein Q 123 65 0.000309 0.0759 3
SRP19 117 80 0.000325 0.0776 6
40S small ribosomal protein 21 155 109 0.000334 0.078 7
G-protein beta2 (GBB2) subunit 391 213 0.000372 0.0848 9
Chk2 55 48 0.000387 0.085 11
SEC11A 112 75 0.000391 0.085 7
SET domain containing (lysine methyltrans-
ferase) 8 (EC:2.1.1.43)
33 16 0.000427 0.0881 8
60S ribosomal protein L40 173 123 0.00044 0.0881 4
SRP54 112 76 0.000443 0.0881 4
peroxiredoxin 4 (EC:1.11.1.15) 261 177 0.000452 0.0881 8
G-protein beta 3 (GBB3) subunit 362 192 0.000454 0.0881 7
ADPRT 431 308 0.00046 0.0881 12
60S ribosomal protein L34 155 105 0.000481 0.0896 7
CD151 17 13 0.000488 0.0896 6
TERT 97 75 0.000497 0.0896 8
Cyclin-H 228 149 0.000522 0.0925 13
SRP72 119 80 0.000549 0.0954 7
Table A.1: NESTs significantly associated with metastatic prostate cancer,
based on data by Yu et al. The table lists all NESTs found to be significantly ac-
tive (assessed through the Wilcoxon signed-rank test, FDR threshold=0.1) in metastatic
prostate cancer compared to primary carcinoma (expression data from (184)).
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Enriched pathway based sets
pathway name set size measured genes p-value q-value pathway source
Ribosome - Homo sapiens (human) 88 62 1.34e-05 0.00957 KEGG
Eukaryotic Translation Termination 89 61 2.05e-05 0.00957 Reactome
Formation of a pool of free 40S subunits 98 71 2.64e-05 0.00957 Reactome
Peptide chain elongation 89 62 2.76e-05 0.00957 Reactome
Eukaryotic Translation Elongation 92 65 2.88e-05 0.00957 Reactome
Signaling by GPCR 893 298 5.83e-05 0.0137 Reactome
RNA Polymerase I Promoter Opening 30 16 6.1e-05 0.0137 Reactome
E2F transcription factor network 120 62 6.63e-05 0.0137 PID
insulin 42 68 0.000103 0.019 INOH
Insulin Synthesis and Processing 115 75 0.000122 0.0191 Reactome
Cell Cycle, Mitotic 276 183 0.000127 0.0191 Reactome
GPCR downstream signaling 831 263 0.000162 0.0209 Reactome
IL5 51 50 0.00017 0.0209 NetPath
insulin Mam 49 66 0.000191 0.0209 INOH
GPCR ligand binding 392 205 0.000191 0.0209 Reactome
Neuroactive ligand-receptor interaction -
Homo sapiens (human)
272 158 0.000202 0.0209 KEGG
PDGFR-beta signaling pathway 58 49 0.000219 0.0214 PID
Muscle contraction 49 40 0.000317 0.0284 Reactome
Non-small cell lung cancer - Homo sapiens
(human)
54 49 0.000325 0.0284 KEGG
Class A/1 (Rhodopsin-like receptors) 291 144 0.000413 0.0342 Reactome
vegf hypoxia and angiogenesis 37 26 0.000465 0.0364 BioCarta
Sema4D induced cell migration and growth-
cone collapse
24 20 0.000483 0.0364 Reactome
Signalling to ERKs 35 31 0.000591 0.042 Reactome
JAK STAT pathway and regulation 121 218 0.000608 0.042 INOH
Signalling to RAS 26 24 0.00065 0.0431 Reactome
role of nicotinic acetylcholine receptors in
the regulation of apoptosis
18 13 0.000732 0.0467 BioCarta
GTP hydrolysis and joining of the 60S ribo-
somal subunit
110 80 0.000767 0.0471 Reactome
BARD1 signaling events 31 25 0.00103 0.0588 PID
Translocation of ZAP-70 to Immunological
synapse
29 17 0.00107 0.0588 Reactome
Validated targets of C-MYC transcriptional
activation
153 67 0.00107 0.0588 PID
Insulin signaling pathway - Homo sapiens
(human)
136 105 0.00112 0.0588 KEGG
Translation 125 92 0.00115 0.0588 Reactome
L13a-mediated translational silencing of
Ceruloplasmin expression
110 79 0.00121 0.0588 Reactome
3, -UTR-mediated translational regulation 110 79 0.00121 0.0588 Reactome
Diabetes pathways 224 149 0.00134 0.0636 Reactome
superpathway of glycolysis, pyruvate dehy-
drogenase, TCA, and glyoxylate bypass
61 28 0.00155 0.0698 HumanCyc
Phosphorylation of CD3 and TCR zeta
chains
31 18 0.00158 0.0698 Reactome
Smooth Muscle Contraction 22 21 0.0016 0.0698 Reactome
DNA Replication 155 102 0.00174 0.074 Reactome
VEGF signaling pathway - Homo sapiens
(human)
75 52 0.00193 0.0754 KEGG
Eukaryotic Translation Initiation 118 86 0.00195 0.0754 Reactome
Cap-dependent Translation Initiation 117 86 0.00195 0.0754 Reactome
human cytomegalovirus and map kinase
pathways
17 15 0.00201 0.0754 BioCarta
ABC transporters - Homo sapiens (human) 44 25 0.00203 0.0754 KEGG
Generation of second messenger molecules 42 27 0.00205 0.0754 Reactome
NGF signalling via TRKA from the plasma
membrane
134 114 0.00228 0.0823 Reactome
Chronic myeloid leukemia - Homo sapiens
(human)
73 65 0.00273 0.0952 KEGG
Mitotic M-M/G1 phases 131 84 0.00279 0.0952 Reactome
Signaling events mediated by VEGFR1 and
VEGFR2
70 57 0.00281 0.0952 PID
Table A.2: Pathways significantly associated with metastatic prostate cancer,
based on data by Yu et al. The table lists all manually defined pathways from Con-
sensusPathDB found to be significantly active (assessed through the Wilcoxon signed-rank
test, FDR threshold=0.1) in metastatic prostate cancer compared to primary carcinoma





AP-MS affinity purification coupled to mass spectrometry
AUC area under the (ROC) curve
CAPPIC cluster-based assessment of protein-protein interaction confidence
DE genes differentially expressed genes
FDR false discovery rate
GO Gene Ontology
GOSemSim Gene Ontology semantic similarity
IMPaLA integrated molecular pathway-level analysis
NC genes NEST center genes
NEST neighborhood-based entity set
PCA protein-fragment complementation assay






The interaction meta-database ConsensusPathDB described in Chapter 2 is freely
accessible through a web interface at http://cpdb.molgen.mpg.de. NEST analysis de-
scribed in Chapter 4 is implemented in ConsensusPathDB’s web interface. Web service
access to part of the functionality of the ConsensusPathDB web interface is available;
it is documented on the ConsensusPathDB web site and the WSDL1 file is available at
http://cpdb.molgen.mpg.de/download/CPDB.wsdl.
The ConsensusPathDB plugin for Cytoscape described in Chapter 2 can be in-
stalled through Cytoscape’s plugin manager, category “Network and Attribute I/O”
The CAPPIC web-based tool described in Chapter 3 is freely accessible at
http://cpdb.molgen.mpg.de/cappic. The source code implementing CAPPIC is avail-
able on the web page.
The IMPaLA web-based tool for pathway-based analyses of large-scale gene ex-
pression and/or metabolomics data is available at http://impala.molgen.mpg.de. Web
service access to IMPaLA is available; the WSDL1 file is available at
http://impala.molgen.mpg.de/download/IMPALA.wsdl and is documented on the IM-
PaLA web site.
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Die menschliche Zelle umfasst eine große Menge verschiedener Biomoleku¨le wie
Nukleinsa¨uren, Proteine und Metabolite. Diese Biomoleku¨le erfu¨llen ihre Funk-
tionen nicht isoliert, sondern durch ein komplexes Zusammenspiel untereinander.
Erkenntnisse u¨ber die Gesamtheit der molekularen Wechselwirkungen, die in der
Zelle stattfinden, ist unentbehrlich fu¨r das Versta¨ndnis zellula¨rer Prozesse auf der
Systemebene. Zum Beispiel ko¨nnen molekulare Interaktionen oft erkla¨ren, wie
Funktionssto¨rungen bestimmter Gene etwa durch Mutation zu einer bestimmten
Krankheit fu¨hren. Gerade wegen diesem Aufkla¨rungspotential molekularer Wech-
selwirkungen wurden zu ihrer Identifizierung unterschiedliche Techniken entwick-
elt. Viele molekulare Interaktionen in der menschlichen Zelle sind bereits entdeckt
und vero¨ffentlicht worden, wenngleich sie scha¨tzungsweise nur einen kleinen Teil
der wirklich existierenden Wechselwirkungen darstellen. Diverse Datenbanken
sind entwickelt worden um Interaktionsdaten, die zum Beispiel u¨ber Datamining
gewonnen werden, systematisch zu sammeln. Vorhandene Interaktionsnetzwerke
werden bereits in verschiedenen Methoden eingesetzt, die zum Ziel haben, neue
Erkenntnisse u¨ber krankheitsrelevante Gene, Stoffwechselwege und Signalwege zu
gewinnen.
Ein tieferes Versta¨ndnis u¨ber normale und krankheitsbedingte zellula¨re Prozesse
auf der Systemebene ist allerdings durch zwei weitere Hauptfaktoren (neben
der Unvollsta¨ndigkeit vorhandener Interaktionsdaten) stark eingeschra¨nkt. Zum
einen sind solche Daten in der Regel fehlerhaft, das heißt, sie enthalten viele
falsch positive Interaktionen. Diese entstehen meistens durch Fehler bei den ex-
perimentellen Messungen oder gegebenenfalls beim Datamining. Zum anderen
sind vorhandene Daten in Hunderten von Datenbanken verstreut, wobei jede
Datenbank Interaktionen nur einer oder weniger Arten entha¨lt: manche Daten-
banken enthalten ausschließlich Proteininteraktionen, wa¨hrend andere auf Gen-
regulationen, metabolische Reaktionen oder Signalwege spezialisiert sind. In der
Zelle wirken all diese Arten von Interaktionen zusammen um biologische Prozesse
zu treiben. Interaktionsdatenbanken mu¨ssen also integriert werden, damit ein
vollsta¨ndigeres Modell der zellula¨ren Biologie entsteht. Eine solche Integration ist
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dadurch erschwert, dass die einzelnen Datenbanken sehr unterschiedliche Daten-
modelle und -formate haben.
Diese Dissertation bescha¨ftigt sich mit den Herausforderungen, dass vorhandene
Interaktionsdaten zum einen fehlerhaft sind und zum anderen in vielen, wenig
u¨berlappenden Datenbanken zerstreut sind.
Zuerst wird eine neue Metadatenbank fu¨r molekulare Wechselwirkungen namens
ConsensusPathDB vorgestellt. Hier werden unterschiedliche Arten von Interak-
tionen aus vielen o¨ffentlichen Ressourcen integriert um ein vollsta¨ndigeres Bild
der molekularen Wechselwirkungen in der menschlichen Zelle zu erzielen. Zur Zeit
sind Wechselwirkungen sowie Signal- und Stoffwechselwege aus sechsundzwanzig
o¨ffentlichen Ressourcen in der Metadatenbank integriert. Deshalb stellt das in der
ConsensusPathDB vorhandene Interaktionsnetzwerk das umfangreichste Modell
der Wechselwirkungen in der humanen Zelle dar. Der Mehrwert der Datenin-
tergation wird anhand einiger Beispiele veranschaulicht. Die Webschnittstelle
der Datenbank (http://cpdb.molgen.mpg.de) bietet zahlreiche Tools fu¨r Daten-
suche, Netzwerkanalyse und -visualiserung, sowie Interaktions- und Pathway-
basierte Analysen von Genexpressionsdaten. Diese stellen wichtige Hilfsmittel
fu¨r Biologen und Molekularmediziner dar.
Zweitens wird eine neue Methode vorgestellt, mir der Proteininteraktionen bezu¨g-
lich ihrer Richtigkeit beurteilt werden. Die resultierenden Konfidenzwerte ko¨nnen
benutzt werden um falsch positive Interaktionen zu detektieren, oder ko¨nnen als
Interaktionsgewichte in netzwerkbasierten Methoden fungieren. Im Gegensatz zu
vielen anderen Methoden werden hier keine Referenzdatensa¨tze oder zusa¨tzliche
Informationen u¨ber die einzelnen Netzwerkelemente beno¨tigt. Solche Daten sind
oft nicht vorhanden, was vergleichbare Methoden zur Konfidenzwertbestimmung
limitiert. Die vorgeschlagene Methode benutzt ausschließlich die Netzwerkstruk-
tur, im Speziellen ihre Modularita¨t, um die Konfidenzwerte zu berechnen.
Drittens wird ein zugleich vollsta¨ndigeres und akkurateres Modell zellula¨rer Wech-
selwirkungen erstellt, indem die vorgestellte Konfidenzwert Methode auf die inte-
grierten Daten aus ConsensusPathDB angewandt wird. Von dem resultierenden
Netzwerk wird in einem neuen Verfahren zur Identifizierung von krankheitsrel-
evanten Genen und Subnetzwerken unter Beru¨cksichtigung von Genexpression-
sprofilen Gebrauch gemacht. Das integrative Verfahren wird auf Genexpressions-
daten aus Prostatakrebspatienten angewandt um sein Potential zu demonstrieren,
Krebsgene richtig zu erkennen.
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